Ambea strengthens its position within LSS through the acquisition of Resursteamet

Resursteamet was founded in 1997 and has 25 day-care units, three speech therapy units and a children's rehab unit. Resursteamet i Stockholm AB, including subsidiaries, has approximately 750 care recipients and approximately 320 employees. Total sales in the acquired companies in 2016, pro forma, amounted to 161 MSEK and EBITA to approximately 23 MSEK. "Resursteamet is an important and attractive addition to Nytida's LSS business, which strengthens our presence in Stockholm and enables new development opportunities in the area. Together, Nytida and Resursteamet become a clear market leader with 36 units and 1,200 places in day-care in the Stockholm county. Through the acquisition, we complement Nytida's leading position in housing with Resursteamet's market-leading position in day-care operations, creating a stronger and wider LSS offer", says Ambea's CEO Fredrik Gren. "We chose Nytida because they have a clear plan for how they want to utilize Resursteamet's operations and skills. Nytida complements Resursteamet within disability care, and has a value base that complies with ours. We have created a trustworthy relationship with Ambea’s and Nytida's management and look forward to continue to develop Resursteamet with Nytida," says Resursteamet's CEO Annika Meinhardt. This report constitutes the type of information that Ambea AB (publ) is obligated to disclose pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was submitted for publication, through the agency of the contact person set out above, on 22 May 2017.

Multiconsult ASA first quarter: Improvement in the LINK arkitektur and International segments. Positive calendar effect.

Group net operating revenues increased 22.3 per cent to NOK 799.7 million, compared to the same quarter last year. The increase in revenues was mainly driven by higher production due to own net recruitment and acquisition of Akvator AS, aarhus arkitekterne A/S and Iterio AB. Growth in net operating revenues was further impacted by the positive calendar effect in the quarter. The billing ratio decreased to 68.4% (69.1%), with a negative effect on net operating revenues. Billing rates were at a similar level to last year.EBITDA for the quarter was NOK 105.5 million, an increase of 81.1 per cent compared to the same period last year. The increase is mainly explained by higher net operating revenues, which more than offset the increase in operating expenses in the quarter."I am pleased to see that Multiconsult begins the year with a very strong quarter. It is encouraging to see the improvement in the LINK arkitektur and International segments. The acquisition of Iterio AB is an important first step towards realising growth in Sweden, in line with the 3-2-1 GO Strategy", says CEO of Multiconsult ASA Christian Nørgaard Madsen.The order backlog remains strong at the end of the first quarter and was NOK 1 966.5, an increase of 12.7 per cent year on year. Order intake during the first quarter increased by 40.7 per cent to NOK 1 073.7 million. Inclusion of the backlog from Iterio AB of NOK 85.4 million in the first quarter 2017 as well as new order intake from aarhus arkitekterne A/S made strong contributions to the increase. There were strong sales within Buildings & Properties, Transportation and Renewable Energy in the quarter. There were many small and mid-size contract awards in the quarter, and the tender pipeline in the transportation sector is promising.Important new contracts this quarter were Greater Oslo Grid Plan with Statnett and Bridge inspection 2017 with the Norwegian roads authority in Norway as well as the Middle Yeywa hydropower plant in Myanmar. Important add-ons to existing contracts this quarter were the Tønsberg hospital, Campus Ås, and Follo line in Norway as well as Neelum Jhelum in Pakistan and Mount Coffee in Liberia.As of 31 March 2017, total assets amounted to NOK 1 519.1 million and total equity of NOK 582.6 million. The group had cash and cash equivalents of NOK 146.9 million, while net interest bearing debt amounted to NOK 9.8 million. The overall market outlook remains fairly positive. Current market rates have stabilised, however the increase in salaries for the Norwegian workforce has led to challenging profitability for the industry in general. Multiconsult's strong market position, flexible business model and wide service offering provides a sound base for further growth, both domestic and international.A presentation of the first quarter 2017 results will be held today, 22 May, at 09:00 CET at Hotel Continental, Stortingsgaten 24/26, Oslo. The presentation will be held by CEO Christian Nørgaard Madsen and CFO Anne Harris. A live webcast from the presentation can be accessed at www.multiconsult-ir.com and http://webtv.hegnar.no/presentation.php?webcastId=52727275 For further information, please contact: Investor relations:    Mirza Koristovic, Head of Investor Relations    Phone: +47 93 87 05 25    E-mail: ir@multiconsult.no Media:    Gaute Christensen, VP Communications    Phone: +47 911 70 188    E-mail: gaute.christensen@multiconsult.no

BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma

Patients recruited into the study will be randomised based on their tumour load and BRAF mutational status* to receive either: · Pembrolizumab (KEYTRUDA®) +/- BGB324, or · Dabrafenib (TAFINLAR®) and trametinib (MEKINST®) +/- BGB324 Endpoints of the study are objective response rate as well as progression free survival, duration of response and overall survival. *Mutations of the BRAF gene are found in up to 50% of patients with advanced melanoma. The mutation causes cells to grow and spread out of control. Dr. Oddbjørn Straume, lead investigator of the trial, consultant oncologist at Haukeland University Hospital and principal investigator at the Center for Cancer Biomakers. commented: “Immune checkpoint inhibitors, such as the anti-PD-1 therapy pembrolizumab, and targeted therapy against BRAF, such as the MAP Kinase inhibitors dabrafenib and trametinib, which have recently been introduced to treat metastatic melanoma have created considerable excitement due their high initial response rates as well as durable responses in a small fraction of cases. However, the development of treatment resistance in patients is common and as a result we are urgently looking at combination strategies to further improve patient outcomes. AXL has been shown to be a key driver of resistance in melanoma to both anti-PD-1 therapy and MAP kinase inhibitors. This is why we believe combinations that include the selective AXL inhibitor BGB324 could hold great promise for a wide range of patients with non-resectable or metastatic melanoma. Consequently, I appreciate the opportunity to offer my patients access to the investigational AXL inhibitor BGB324 in this Phase Ib/II clinical trial and look forward to drive the opening of additional trial sites across Norway later this year.” Comprehensive biomarker programme in collaboration with Norwegian and US investigators.   In parallel with the clinical trial, leading Norwegian experts in treating melanoma together with collaborators at Massachusetts Institute of Technology and Harvard Medical School (Boston, USA) are conducting a comprehensive programme of explorative biomarker analyses. The high degree of innovation, excellent clinical rationale and high scientific value of this trial was recently recognised by generous grant funding by the Norwegian Health Authorities. Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We congratulate Dr. Straume on the start to this exciting study, which we believe is highly representative of real world practice for treating advanced melanoma. We and others have published encouraging research showing AXL’s role in driving mechanisms that enable tumour cells to go unnoticed by the immune system and also to build resistance to therapies, as well as the potential of BGB324 to counteract these traits of tumour aggressiveness in a wide range of cancers. Based on these data we see a clear rationale for combining our first-in-class AXL inhibitor BGB324 with immune checkpoint blockade or targeted agents in multiple cancer indications. We look forward to results from this new study, as well as from further combination studies we have planned with BGB324 and pembrolizumab in advanced lung cancer and triple negative breast cancer, which we are intending to start in the near future.”    About BerGenBio ASA BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BGB324, is a selective, potent and orally available small molecule AXL inhibitor in Phase II clinical development in four major cancer indications. It is the only selective AXL inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with MSD. The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors including BGB149, anti-AXL monoclonal antibody. For further information, please visit: www.bergenbio.com   About Investigator-sponsored Trials Investigator-sponsored clinical trials are clinical trials proposed by front-line patient-facing physicians who act as the regulatory sponsor and are supported by industry in bespoke clinical development partnerships. The industry partner does not assume the role of sponsor according to European or US regulatory guidelines, but may offer support in a variety of different ways, such as providing investigational medicinal product at no cost. About melanoma Melanoma is the most serious type of skin cancer as it may spread to lymph nodes and distant organs if not discovered in time. Melanoma occurs when the cells that colour the skin, the so-called melanocytes, start to divide uncontrollably. It is estimated that in 2016, there have been almost 150,000 melanoma diagnoses in the US alone. If detected very early, melanoma has a good prognosis; for patients with advanced melanoma, however, the probability of surviving 5 years or longer is less than 20%. References Straume et al. A Phase Ib/II randomized open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma. AACR 2017 Abstract. Presented April 2017. http://www.targetedonc.com/videos/bgb324-with-pembrolizumab-or-dabrafenibtrametinib-in-melanoma  KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Genentech/Roche, TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc. -Ends- Contacts   Richard Godfrey CEO, BerGenBio ASA media@bergenbio.com +47 917 86 304 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

One Sea - Autonomous Maritime Ecosystem introduced roadmaps to autonomous shipping

The One Sea ecosystem, founded in 2016, represents exceptionally advanced co-creation where global leaders in their industries work to reach their joint goal of autonomous traffic. The founding partners in the One Sea – Autonomous Maritime Ecosystem are ABB, Cargotec (MacGregor and Kalmar), Ericsson, Meyer Turku, Rolls-Royce, Tieto and Wärtsilä. The association of Finnish Marine Industries supports the work, and the Finnish funding agency Tekes has invested in the ecosystem. The leader of One Sea is DIMECC.  “Our One Sea ecosystem is the natural next step in the digital transformation of the marine industry. Several new business initiatives in the autonomous maritime traffic have already been started and can be expected in the future. The companies and organisations collaborating in One Sea are forerunners in their respective fields and the fact that our ecosystem is industry-driven separates it from many of the more or less academic exercises. One Sea ensures a well-researched, tested and highly capable autonomous shipping network”, comments Harri Kulmala CEO of DIMECC.  Tieto wants to participate actively in open ecosystems and co-innovation. Tieto already has a strong role in e.g. financial ecosystems as Tieto develops Finland’s first real-time multi-banking platform for mobile payments, named Siirto. Now Tieto is seeking an active role in an IoT ecosystem for autonomous maritime traffic in the Baltic Sea.  “As we are capturing the opportunities provided by the data-driven economy, for Tieto co-innovation with customers and partners is vital. This is increasingly being done in ecosystems in which Tieto is also actively seeking a bigger role. Partnering with global players in autonomous traffic ecosystem, Tieto is seeking new business initiatives and new opportunities of the future data-driven world”, says Ari Järvelä, Head of Data-driven Businesses, Tieto.   “Very soon Internet of Things will be seamlessly integrated in our everyday life, and we will also see a growing number of real-life applications for robotics and AI. Here autonomous traffic is one key area, and Tieto has been actively participating in related networks and development work. While autonomous cars have been in focus, the development for road traffic has synergies to sea - One Sea – Autonomous Maritime Ecosystem is a great example of seeking new possibilities to co-create future innovations”, says Tom Leskinen, Head of Product Development Services at Tieto.  The effort to create products and develop software and solutions to enable autonomous traffic has already been started in the participating companies. In order to promote autonomous traffic around the globe, the One Sea – Autonomous Maritime Ecosystem has taken upon itself to introduce roadmaps towards an autonomous maritime future. The roadmaps include a timeline towards 2025 and major themes to be investigated and levels of maritime autonomy – all minimising accidents, decreasing the environmental footprint of marine traffic, and advancing possibilities for efficiency improvement and new commercial ventures. The roadmaps have been created by the representatives of the companies included in the ecosystem and verified by a national Advisory board as well as an International Advisory Board.  The expected timeline for autonomous maritime traffic shows that the regulators will have to increase the pace at which new regulations are approved. The technologies are advancing at such a speed that the rules and regulations risk becoming obsolete. Fortunately, forward thinking national and international units are doing their best to enable autonomous traffic even within such a short timeline.  In addition, One Sea – Autonomous Maritime Ecosystem is currently working on the roadmaps around themes as Operational, Technical, Security, Regulatory, Traffic Control and Ethical. Roadmaps for these important themes will be introduced to the public and other maritime actors in due course. There is ongoing research and discussions with related parties regarding each of the themes and jointly they will enable commercial autonomous maritime traffic by 2025.  Read more about the One Sea: Finnish-based Autonomous Maritime Ecosystem’s website promoting autonomy related efforts https://www.oneseaecosystem.net/  About Autonomous ships: Autonomous ships are the future of modern marine traffic. Autonomous ships operate in an ecosystem, where decision-making is based on data, smart algorithms, artificial intelligence and ultimate optimisation. The possibilities autonomy and digitalisation bring to the naval environment will shape traditional marine traffic to the next level. Roles of the on-board crew, artificial intelligence and the remote-control crew ashore will be redefined and assessed. One Sea ecosystem is a smart environment, where intelligent devices and solutions read Big Data, analyse it, communicate with each other and furthermore make decisions independently. The magnitude of the benefits autonomy brings marine traffic can be calculated in costs, reliability and efficiency, while there exist multiple possibilities in creating completely new revenue streams with innovations created along the way.  Infograph: Timeline for autonomous ships in the Baltic Sea Pictures: One Sea Alliance The founding partners in the One Sea – Autonomous Maritime Ecosystem: ABB ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing more than a 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 135,000 employees. www.abb.com Cargotec Cargotec (Nasdaq Helsinki: CGCBV) enables smarter cargo flow for a better every day with its leading cargo handling solutions and services. Cargotec's business areas Kalmar, Hiab and MacGregor are pioneers in their fields. Through their unique position in ports, at sea and on roads, they optimise global cargo flows and create sustainable customer value. Cargotec's sales in 2016 totalled approximately EUR 3.5 billion and it employs over 11,000 people. www.cargotec.com Ericsson Ericsson is a world leader in communications technology and services. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential.  www.ericsson.com Meyer TurkuMeyer Turku Oy employs over 1,600 persons and specializes in building highly complex, innovative and environmentally friendly cruise ships, car-passenger ferries and special vessels. Together with two sister shipyards in Germany, Meyer Werft in Papenburg and Neptun Werft in Rostock, Meyer Turku is one of the world’s leading cruise ship builders. The successful shipbuilding tradition in Turku has been continuing since 1737. The company is currently building cruise ships for TUI Cruises. The company will also build two cruise ships for Costa Crociere, Carnival Corporation and Royal Caribbean International. www.meyerturku.fi Rolls-RoyceRolls-Royce’s vision is to be the market-leader in high performance power systems where our engineering expertise, global reach and deep industry knowledge deliver outstanding customer relationships and solutions. We operate across five businesses: Civil Aerospace, Defense Aerospace, Marine, Nuclear and Power Systems. www.rolls-royce.com  Tieto Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. www.tieto.com  WärtsiläWärtsilä is a global leader in advanced technologies and complete lifecycle solutions for the marine and energy markets. By emphasising sustainable innovation and total efficiency, Wärtsilä maximises the environmental and economic performance of the vessels and power plants of its customers. In 2016, Wärtsilä's net sales totalled EUR 4.8 billion with approximately 18,000 employees. The company has operations in over 200 locations in more than 70 countries around the world. Wärtsilä is listed on Nasdaq Helsinki. www.wartsila.com   DIMECC DIMECC Ltd. is the leading co-creation platform for digital transformation. DIMECC combines the leading companies from manufacturing and digital industries to the academic research. DIMECC’s customers outperformed the non-customers from respective industries during 2009-2014 by all financial measures. www.dimecc.com

Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander

The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors. Dr. Birgitte Volck is Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline headquarters in London, UK. Dr. Volck has extensive development experience with orphan drugs and more than 17 years of experience from senior roles in the biotech industry. Prior to GlaxoSmithKline, Dr. Volck served as Chief Medical Officer and Head of Development at Sobi and has also held senior roles at Amgen, Genzyme and Pharmexa. Throughout her industry career, Dr. Volck has led early and late stage development programs and executed product commercialization and regulatory strategies, particularly for new medicines in the orphan space. She holds a medical degree and a PhD from Copenhagen University in Denmark. Dr. Volck stated: “I am passionate about bringing new treatment options to patients with rare diseases and I am pleased to be invited to work with a company that shares this vision. This is an important time for Wilson Therapeutics as it embarks on a pivotal study for WTX101 and begins to build its commercial expertise. I am looking forward to engaging with the board of directors and imparting the knowledge I have gained through many years in the rare disease space to help the Company realize its long-term vision.” Dr. Björn Odlander is Managing Partner and co-founder of HealthCap, a leading European venture capital firm investing in breakthrough therapies for diseases with high unmet medical needs. Dr. Odlander has more than 25 years of experience from the biotech industry and he has been involved in a number of companies that have brought novel therapies for rare diseases to market. He holds a medical degree and a PhD from the Karolinska Institute in Stockholm. “I was a member of the board of Wilson Therapeutics for two years after the company’s inception. We had already seen back then that WTX101, as a first in class once-daily drug with a unique mechanism of action, had the potential to revolutionize the treatment for this severe disease. Since then the company has continued to evolve exceptionally well so it is very exciting to be back”, said Dr. Björn Odlander. “Birgitte has a long and successful career in the biopharma industry with an impressive track record in R&D and medical affairs”, said Andrew Kay, Chairman of the Board of Wilson Therapeutics. “Having access to her rare disease focus and extensive experience and leadership will be extremely valuable for the board as we move forward with our development and commercialization plans for WTX101. In addition, Björn is one of the most experienced biotech investors in Europe, also with extensive orphan drug expertise, so we are of course thrilled to welcome them both to the Board.”  About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information.  For further information contact:Jonas Hansson, CEO, Wilson Therapeutics ABTelephone: +46 8 796 00 00Email: jonas.hansson@wtx.se Wilson Therapeutics AB (publ)Org nr 556893-0357Kungsgatan 3SE-111 43 Stockholm

GBO announces final outcome in the offer for Vigmed

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share. On 13 April 2017, the Offer consideration was increased to SEK 1.20 in cash per share. On 3 May 2017, GBO declared the Offer unconditional and that the Offer will be completed. The acceptance period expired on 17 May 2017 and, as previously communicated, the acceptance period will not be extended. The shares tendered in the Offer, together with shares that GBO has acquired outside the Offer and the newly issued shares that GBO has subscribed in a directed share issue, amount to in aggregate 61,709,589 shares in Vigmed, corresponding to 84.47 percent of the total number of outstanding shares and votes in Vigmed. At the end of the acceptance period on 17 May 2017, the Offer had been accepted by shareholders representing in total 48,009,383 shares in Vigmed, corresponding to 65.72 percent of the total number of outstanding shares and votes in Vigmed (which would correspond to 73.02 percent of the total number of outstanding shares and votes in Vigmed prior to Vigmed's directed share issue announced on 8 May 2017). GBO has outside the Offer acquired in total 6,394,651 shares in Vigmed, corresponding to 8.75 percent of the total number of outstanding shares and votes in Vigmed. None of these shares have been acquired at a price which exceeds the consideration in the Offer. As a part of supporting Vigmed's need of a capital, GBO has on 7 May 2017 participated in a directed share issue in Vigmed, where GBO subscribed 7,305,555 new shares at a subscription price of SEK 1.10 in cash per share. For further information about the directed share issue, please refer to the press release published by Vigmed on 8 May 2017. Settlement in respect of shares in Vigmed duly tendered in the Offer during the last extension of the acceptance period is expected to be initiated on or about 25 May 2017. Other than the shares in Vigmed acquired as set out above, GBO does not currently own or control any shares or financial instruments that provide a financial exposure equivalent to a holding of shares in Vigmed. GBO might acquire additional shares in Vigmed on the market or through private transactions. "We are pleased to conclude that a significant majority of the shareholders of Vigmed have appreciated GBO's offer and already sold their shares to GBO. As a long-term shareholder GBO is now ready to engage in the challenge of developing Vigmed's business and product portfolio, including to support Vigmed in the significant capital injections that will be required to satisfy Vigmed's need of liquidity in order to realize its long-term prospects", said Rainer Perneker, CEO of the Greiner Bio-One group. Greiner Bio-One GmbH

Diamyd Medical submits application to the Medical Products Agency for the DIAGNODE-2 trial

“Our application for a follow-up clinical Phase II trial with the diabetes vaccine Diamyd® is an important milestone," says Ulf Hannelius, CEO of Diamyd Medical. “I am very pleased with how the preparations progress and impressed by the efficiency and dedication that permeates the work of all involved.” Diamyd Medical collaborates with the global contract research company TFS Trial Form Support International, and now follows the applications to have the trial approved by the respective Competent Authorities in Spain and the Czech Republic, as well as to the relevant Ethics Committees. DIAGNODE-2 is expected to start recruiting patients this autumn 2017. The trial is financed by Diamyd Medical, sponsor of the trial, through funds from the ongoing rights issue with the subscription period 10 - 24 May 2017. About DIAGNODE-2DIAGNODE-2 includes approximately 80 patients aged 12-24 years, recently diagnosed with type 1 diabetes, and the patients will be followed for 15 months. The aim of the trial is to evaluate the effect of the treatment in preserving the patients' insulin producing capacity. The trial is based on the ongoing open-label pilot trial DIAGNODE‑1, where preliminary results indicate that the intralymphatic administration of the diabetes vaccine Diamyd® appears to increase the effect of the vaccine as compared to injecting under the skin (subcutaneous). The Coordinating Investigator for the trial is Professor Johnny Ludvigsson at Linköping University. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical trials are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Telia Company acquires Finnish ICT service company Nebula

Nebula Top Oy was founded in 1997 and offers highly automated and standardized cloud infrastructure services with a strong customer centric model. Nebula’s 145 employees serve a customer base of approximately 44,000 who generate 90 percent subscription-based recurring revenues.  In 2016 Nebula reported net sales of EUR 35.1 million and an adjusted EBITDA of EUR 13.5 million. Based on its 2016 results, the purchase price corresponds to an EV/EBITDA multiple of 12.8x, not considering synergies. Telia Company expects to generate synergies above EUR 10 million within a 3 year period from cross sales as well as production cost savings. In 2018, Telia Company will open one of the largest open data centers in Finland to support digitalization and infrastructure services. “I’m happy to welcome Nebula’s employees and its customers to Telia Company. This is another important step in developing the customer experience by adding a complete portfolio of cost efficient and high level automated services. We are looking forward to working with and learning from Nebula’s very competent staff,” says Johan Dennelind, President and CEO of Telia Company. The acquisition of Nebula Top Oy from the main owner Ratos and other minority owners is subject to approval from the Finnish Competition and Consumer Authority and is expected to be completed in the third quarter of 2017. Following a successful rebranding in March 2017, Telia continues to develop and improve its services to the Finnish customers. For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .   Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.   We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com.  

TalkPool increases its order intake from large European telecom operators

“TalkPool’s order intake from clients in Europe increased in the second half of 2016 and has continued to accelerate during the first four months of 2017 while order levels from clients in Africa and the Americas have remained stable. Europe generated almost a third of TalkPool’s overall orders in the first four months of 2017”, comments Erik Strömstedt CEO of Talkpool.During the period January to April 2017, approximately 26% of Talkpool revenues relates to the African market and originates from many countries, whereas the 42% of the total revenues relates to the Americas and stems from only two markets.Network services order volumes from Digicel in the Carribbean have remained unchanged during many years but its share has reduced to 37%, down from over 50% a year ago, as business from other clients is growing. Orders from China-based equipment vendor Huawei continue to increase while the share of orders from Swedish Ericsson, with whom TalkPool has a close relation, is continuing to decline.TalkPool continues to get a wide range of IoT orders but the order volumes are still modest.This information is information that TalkPool is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 22 May, 2017.For more information, please contact:Erik Strömstedt, CEO of TalkPool, erik.stromstedt@talkpool.com, Tel: +41 81 250 2020About TalkpoolTalkPool builds, maintains and improves telecommunication networks globally. Through its cutting-edge technical expertise, long experience and agile business model, TalkPool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, TalkPool is one of few companies with actual solutions and contracts in place in the exciting IoT-market. Remium Nordic AB is TalkPool’s Certified Advisor for Nasdaq First North.

Street space in Tripla brings more life to Pasila

The most important life in the city takes place between buildings and not indoors, says urban developer Janne Viitamies. This has also been taken into account in the new urban centre, Tripla. Street space is a natural part of the shopping centre, and passers-by do not need to know whether they are in or outside the mall. Many of us here in Finland like to meet others outdoors—whether for a morning coffee or brunch, after-work conversation with drinks or just to enjoy an ice-cream, watching people passing by. The best thing about the city is the street life. Therefore, it is not without significance what the street space of a shopping centre is like. Right from the beginning of the planning for Tripla in Pasila and its shopping centre, the Mall of Tripla, it was clear that the planning work would also include the outdoor spaces. Kalle Soini mentions that one of the design principles has been that the building’s outer spaces enliven the street space. Soini heads the architectural design of Tripla at Soini & Horto Oy. The guiding idea is that a modern centre made for the future cannot be a confined space. “Entrances must be positioned so that they are a natural part of the street network, so that the shopping centre will become part of the pedestrians’ daily routes.” In the Mall of Tripla, each of its four commercial floors is connected to street space. Urban experience comes from people Urban developer Janne Viitamies completed his doctorate last year. The name of his dissertation was Kenen Aleksi, sen Helsinki (roughly, “Who controls Aleksanterinkatu, controls Helsinki”). The dissertation explains how the pedestrian city centre in Helsinki was born and how it has evolved. Viitamies points out that the urban structure is formed in the street, both mentally and socially. The urban experience is born out of the fact the people move about in the streets. That there is life in the city. “If you cannot see any people, the city feels dull. The vibrancy of city centres comes from people moving about, spending time. The sign of a living city is its people,” Viitamies says. He urges us to reflect on where we go when we visit new cities abroad: we go to places where there are others, that is, places that attract us. “When people are asked to name the centre of Helsinki, one place that is often mentioned is the Three Smiths Square. This is because the square is a very busy pedestrian route. Each city has its own “Three Smiths Square”. For instance, in New York it’s Times Square.” In recent years, the idea that life in the city is lived between buildings and not indoors, has gained popularity in Finland as well. Pasila development plans go back a long time Dan Mollgren, Project Manager at Helsinki City Planning Department, points out that, for the past hundred years in the long history of the city, Pasila has been regarded as an important urban hub. Already Eliel Saarinen envisaged that the area is an important meeting point. Alvar Aalto, too, had city centre plans for Pasila. “When designing the new centre for Pasila, we soon discovered that it had to be big, even bigger than anybody had thought. At the same time, we began to realize that the area cannot be designed for just one function but must be created for a number of different uses. And those different uses must overlap.” Mollgren says that what makes Tripla sustainable and attractive in the long run is the quality of indoor and outdoor space. Shopping malls were originally created to mimic old towns and their narrow streets. Cities, in turn, took the idea of shopping malls further and began to set up pedestrianized streets in their centres. The cycle continues. Now, with the Mall of Tripla, the city centre goes indoors again, with the city and the shopping mall forming a seamless whole together with the street space. The indoor alleyways and squares are easily accessible from the terraces in the street space. Public art adds to quality As a classic example of a successful dialogue between a shopping mall and its surrounding milieu, Viitamies mentions the Galleria Vittorio Emanuele II, located in Piazza del Duomo, Milan. People can wander in the area without even realizing that from time to time they enter the mall. Kalle Soini remarks that this idea has also been a major factor in the design of Tripla. Even materials, such as the granite in the station, continue to the shopping centre. “We designed a large series of public spaces including the station square and the station hall, the middle block and the residential park, all of which are public or semi-public spaces. Not even the yards will be closed spaces, as has been customary.” Furthermore, the bridge joining East and West Pasila will be built to resemble a wide urban boulevard rather than a bridge. In Soini’s view, good design is based on carefully evaluating the impact of a new building on the environment and ensuring that it gives something to its environment. “In Tripla’s case, it gives a lot.” Soini emphasizes that close cooperation with the City of Helsinki has been a major factor in the success of the project. For example, the public transport terminal in front of the station will also be a natural part of the whole. He also commends investment in public art. The City of Helsinki and YIT organized a general competition for the art of Fredikanterassi. The competition was won by Akseli Leinonen with his work Ecology stone. “The quality objectives of public outdoor space have been kept high. In addition, the importance of artistic values and aesthetics to people has been well understood,” Soini says. The Fredikanterassi art competition was won by Akseli Leinonen with his work Ecology stone. * The jury mentioned that the work is dramatic and contains a strong tension, creating an interesting contrast between nature and the built environment. The work lives subtly with the times. * The competition sought permanent, site-based works that would reinforce Fredikanterassi’s character as a meeting and entertainment venue. * The first phase of the competition was attended by 148 proposals, eight of which made it to the short list. Further information:Pirjo Aalto, Commercial Development Director, YIT Construction Ltd, tel. +358 50 500 2013, pirjo.aalto@yit.fiHeidi Kauppinen, Communications Manager, YIT Construction Ltd, tel. +358 40 574 3170, heidi.kauppinen@yit.fiHanna Malmivaara, Vice President, Communications, YIT Corporation, tel. +358 40 561 6568, hanna.malmivaara@yit.fi Read also: Successful urban centre serves, entertains and pampers residents  YIT creates a better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life into sustainable cities. We want to focus on caring for customers, visionary urban development, passionate execution and inspiring leadership. The engine of our growth is urban development involving partners. We operate in Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion and we employ about 5,300 people. Our share is listed on Nasdaq Helsinki.www.yitgroup.com 

Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

Isofol Medical AB, a clinical stage oncology company, announces the release of an abstract from a retrospective study that will be presented at the ASCO Annual Meeting, which will be held June 2–6, 2017, in Chicago. Abstract #11028: Failure rate of standard rescue with leucovorin for high-dose methotrexate (HDMTX) in osteosarcoma http://abstracts.asco.org/199/AbstView_199_185637.html Poster Session: Sarcoma; Sunday, June 4, 08:00-11:30 a.m. CDT, Hall A, Poster Board #351Authors Mikael Eriksson, Karin Ganlöv and Louise Kvistgaard will be present during the poster session.Citation: J Clin Oncol 35, 2017 (suppl; abstr 11028) For more information, please contact:Anders Rabbe, CEO, Isofol Medical ABE­mail: anders.rabbe@isofolmedical.comPhone: +46 (0)707 646 500 About Modufolin®Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert it’s effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin®  is currently being evaluated in two clinical Phase II studies. About Isofol Medical ABIsofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is  FNCA Sweden AB  www.isofol.se

Ahlstrom-Munksjö Considers Issuance of New Notes and Announces a Voluntary Tender Offer of its Outstanding Notes Maturing in 2019

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NEW NOTES (AS DEFINED BELOW), THE TENDER OFFER (AS DEFINED BELOW) OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.  AHLSTROM-MUNKSJÖ OYJ STOCK EXCHANGE RELEASE, MAY 22, 2017 at 10:45 CEST Ahlstrom-Munksjö Oyj (the “Company”) is considering the issuance of new euro-denominated fixed rate notes with an expected maturity of five years (the “New Notes”). The potential issue is expected to take place in the near future subject to market conditions. The target size of the issue is approximately EUR 200 million. At the same time, the Company announces that it invites the holders of its EUR 100 million 4.125 per cent. notes due 15 September 2019 (ISIN: FI4000108501) (the “2019 Notes”) to tender the 2019 Notes for cash on the terms and conditions set out in the Tender Offer Memorandum dated May 22, 2017 (the “Tender Offer”). Further, the Company intends to exercise its voluntary total redemption right under the terms and conditions of the 2019 Notes, to redeem any outstanding 2019 Notes not repurchased as part of the Tender Offer on or about September 15, 2017. Pursuant to the Tender Offer, the Company proposes to accept for purchase any and all of the 2019 Notes, although the Company reserves the right, in its sole discretion, to decide on acceptance of the 2019 Notes for purchase, including not to accept any 2019 Notes for purchase. Whether the Company will accept for purchase any 2019 Notes validly tendered is subject to, without limitation, the pricing of the issue of the New Notes and the signing by the Joint Lead Managers and the Company of an issuance agreement. The purchase price of the 2019 Notes is EUR 1,032.00 per EUR 1,000.00 in principal amount of the 2019 Notes. Accrued and unpaid interest will be paid in respect of all 2019 Notes validly tendered and delivered and accepted for purchase. The Offer Period closes at 4:00 p.m. Finnish time (EET) on June 2, 2017. The indicative Tender Offer results will be announced following the closing of the Offer Period, on or about June 5, 2017. The Tender Offer results will be announced on or about June 5, 2017. The settlement date of the Tender Offer is subject to the completion of the issue of the New Notes, expected to be on or about June 9, 2017 and no later than June 14, 2017. The purpose of the arrangement is to proactively manage upcoming debt redemptions and to extend the average debt maturity profile of the Company. Nordea Bank AB (publ) and Skandinaviska Enskilda Banken AB (publ) act as Dealer Managers, and Nordea Bank AB (publ), Finnish Branch acts as Tender Agent for the Tender Offer. Information in respect of the Tender Offer may be obtained from the Dealer Managers. Nordea Bank AB (publ) and Skandinaviska Enskilda Banken AB (publ) act as Joint Lead Managers and Danske Bank AB (publ) acts as Co-Lead Manager for the issue of the New Notes. Dealer Managers: Nordea Bank AB (publ), +45 6161 2996, bibi.larsen@nordea.com/nordealiabilitymanagement@nordea.com Skandinaviska Enskilda Banken AB (publ), +46 8 506 230 09, SEBLiabilityManagement@seb.se Tender Agent: Nordea Bank AB (publ), Finnish Branch Important Information The information contained herein is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or such other countries or otherwise in such circumstances in which the release, publication or distribution would be unlawful. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the New Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. This communication does not constitute an offer of securities for sale in the United States. The New Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of any state of the United States and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. This communication does not constitute an offer of New Notes to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the New Notes. Consequently, this communication is directed only at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (iii) high net worth entities falling within Article 49(2) of the Order and (iv) other persons to whom it may lawfully be communicated (all such persons together being referred to as "relevant persons"). In addition, this communication is, in any event only directed at persons who are "qualified investors" pursuant to the Prospectus Directive (2003/71/EC, as amended). Any investment activity to which this communication relates will only be available to, and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. For further information, please contact:

TRADEcho strengthens position as a market leader as 259 firms now contracted with TRADEcho for MiFID II trade reporting

TRADEcho ’s client list includes a broad range of clients in every MiFID asset-class, from the largest Tier 1 buy-side and sell-side clients to smaller regional brokers and other MiFID investment firms. With less than 230 days until MiFID II firms are beginning to recognise the importance of finalising their MiFID II transparency arrangements; and an increasing number are choosing TRADEcho as their preferred MiFID II multi-asset class trade and quote publication service. A significant factor that has driven TRADEcho’s recent sales momentum is the launch of an Assisted Reporting Service. MiFID II introduces the seller’s obligation, such that buy-side firms can no longer outsource the liability of correctly publishing trades to their sell-side counterparty. It is, however, possible for brokers to assist clients in publishing trades, and TRADEcho’s Assisted Reporting Service facilitates this, helping firms meet their regulatory obligations*. Assisted reporting is anticipated to be a service that the sell side will provide to many customers. TRADEcho remains the only all-asset class assisted reporting solution for firms wanting to use only one APA. Many firms are also leveraging TRADEcho’s unique APA agnostic Smart Report Router(SRR) - a utility for the marketplace - to faciliate this and satisfy customer demand. In addition to the increasing number of firms signed up to the service, TRADEcho will strengthen its network with the migration of firms currently trade reporting on London Stock Exchange, taking place on 19 June 2017.  Jamie Khurshid, CEO of Boat Services said: “Simplifying complex business problems is at the heart of what we do and we are proud to deliver services that the market sees value in and has asked for. TRADEcho is in a great position for MiFID II and we expect continued sales growth throughout 2017” Scott Bradley, Head of Sales for LSE Cash Secondary Markets & Turquoise said: “TRADEcho brings together an unparalleled wealth of knowledge and expertise in both on-exchange and OTC trade reporting which provides true peace of mind to clients looking for a solution to meet their MiFID II post trade requirements. Existing LSE members and new customers to the service can also gain access to a host of value add tools and services designed to navigate this potentially challenging landscape” For further information, please contact:Per Loven,Commercial Director,TRADEchoTel: +44 (0) 2038721944per.loven@cinnober.comwww.tradecho.com *TRADEcho are running a webinar on their Assisted Reporting offering on May 31. Email demos@tradecho.com to register. About TRADEcho TRADEcho is the suite of reporting services hosted and operated by the London Stock Exchange, brought to market in partnership with Boat Services. TRADEcho has been formed in direct response to client feedback for compliant, simplified and cost effective reporting services. With MiFID II on the horizon, the London Stock Exchange and Boat chose to combine their strengths to form a team of industry, regulatory and technical experts. The existing London Stock Exchange and Boat MiFID trade reporting services are currently being combined, bringing together the complementary strengths of Boat’s OTC reporting and the London Stock Exchange’s primarily on exchange reporting. Alongside the partners in the group, such as UnaVista and MTS, TRADEcho truly is a one-stop shop for pre and post-trade reporting. For further information, please visit www.tradecho.com. About Boat Services Boat was established in 2007, offering MTFs, SIs and investment firms an easy and cost-efficient way to comply with transparency obligations. Ever since, Boat has operated with exceptional uptime, and is the trade data monitor (TDM) with the most comprehensive offering of reportable instruments, including more than 10,000 stocks and ETFs across Europe, the Swiss and Russian markets. Ever since Boat’s inception, its core technology has been supplied by Cinnober . In 2014 Cinnober acquired Boat ensuring the continued existence of a specialized provider, committed to the long-term delivery of transparency services to the benefit of the industry. In 2016 Boat expanded its product offering to include services for the London Bullion Market Association (LBMA) and the insurance industry. For further information, please visit www.theboatplatform.com. About London Stock Exchange GroupLondon Stock Exchange Group (LSE.L) is a diversified international market infrastructure and capital markets business sitting at the heart of the world's financial community. The Group can trace its history back to 1698. The Group operates a broad range of international equity, bond and derivatives markets, including London Stock Exchange; Borsa Italiana; MTS, Europe's leading fixed income market; and Turquoise, a pan-European equities MTF. It is also home to one of the world’s leading growth markets for SMEs, AIM. Through its platforms, the Group offers international business and investors unrivalled access to Europe's capital markets. Post-trade and risk management services are a significant part of the Group’s business operations. In addition to majority ownership of multi-asset global CCP operator, LCH.Clearnet Group, LSEG operates CC&G, the Italian clearing house; Monte Titoli, the T2S-ready European settlement business; and globeSettle, the Group’s newly established CSD based in Luxembourg. Headquartered in London, with significant operations in North America, Italy, France and Sri Lanka, the Group employs approximately 4,700 people. Further information on London Stock Exchange Group can be found at www.lseg.com

“The Angry Birds Movie 2” takes flight as Columbia Pictures and Rovio Entertainment set creative team, release date

Following the success of The Angry Birds Movie, which slingshot to nearly $350 million in worldwide box office and launched a global movie brand, Columbia Pictures in association with Rovio Entertainment Ltd. are once again joining forces on the next high-velocity adventure as the flightless birds and scheming green piggies take their beef to the next level in The Angry Birds Movie 2; Sony Pictures will distribute the sequel. The sequel is planned to hit theaters on September 20, 2019, coinciding with the 10th anniversary of the original Angry Birds game. The Angry Birds Movie 2 will be directed by Thurop Van Orman (The Marvelous Misadventures of Flapjack, Adventure Time). Van Orman recently worked at Disney and Sony Pictures Animation.  The film will be co-directed by John Rice (King of the Hill, Rick and Morty), who served as lead storyboard artist on The Angry Birds Movie and directed the popular Angry Birds Hatchlings shorts. The film will be produced by John Cohen (Despicable Me, The Angry Birds Movie). Peter Ackerman (FX’s “The Americans,” Ice Age) is writing the screenplay. The talented team at Sony Pictures Imageworks will once again be handling the animation for the film, which will be with the collaboration of Sony Pictures Animation. Also returning from The Angry Birds Movie will be production designer Pete Oswald and character art director Francesca Natale. “We are thrilled to be teaming up again with Sony Pictures after the fantastic cooperation in the first movie and I can't wait to experience the new journey in the upcoming film,” commented Kati Levoranta, CEO of Rovio Entertainment. “Rovio is continuing to focus on creating exciting new stories and experiences around our games and we’re eager to take fans back into the vibrant Angry Birds world on the big screen.” “The Angry Birds Movie took the world by storm last year, creating a whole new legion of fans worldwide,” said Sanford Panitch, president of Columbia Pictures. “We had an incredible experience working with our friends and creative partners at Rovio, and now we – including our team at Sony Pictures Imageworks – are ready to launch into this next adventure.”

Samuel Rotstein, MD, Ph.D., appointed as Scientific Advisor to Biovica

  Dr Rotstein received his Ph.D at Karolinska Institutet and has worked as an oncologist for almost 40 years. He was previously Head of Department at the Oncology Clinic at Danderyd Hospital where he together with his colleagues built and managed a highly-appreciated breast cancer clinic. As one of Sweden's leading oncologists, he was honored last year with the Swedish Breast Cancer Patient Advocacy Association's (BRO) Award 2016. Samuel Rotstein is currently working as a physician at Radiumhemmet, Karolinska University Hospital.   In the role as Scientific Advisor to Biovica, Samuel Rotstein, will contribute with his experience & expertise and assist the company in its extensive clinical study program and in the development of the company's products.   "We are very pleased to have Dr. Samuel Rotstein as Medical Advisor to Biovica and we are looking forward to our collaboration. His experience in oncology and in breast cancer will be very valuable for Biovica and our long-term objectives to assist patients. Our goal is through our technology contribute to best possible treatment for cancer patients", says Anders Rylander, CEO Biovica.   "I'm looking forward to working with Biovica. As more cancer treatments becomes available and more individualized, greater demands arise for improved diagnostic tools and evaluation methods in order to give the patient the optimal treatment", says Dr. Samuel Rotstein.

Alaska Airlines and Finnair announce frequent flyer partnership

Alaska Airlines and Finnair are teaming up to give members of their frequent flyer programs the opportunity to earn miles/points on both airlines as Finnair expands its wings with new flights from San Francisco. “We’re thrilled to be partnering with European-favorite Finnair, as they launch their first West Coast service from our San Francisco hub to Helsinki on June 1,” said Andrew Harrison, Alaska Airlines executive vice president and chief commercial officer. “Our Mileage Plan members will be able to fly Finnair to over 60 destinations in Europe from San Francisco, Chicago and New York’s JFK.” Alaska Airlines recently announced a major expansion of its San Francisco service. Alaska, along with Virgin America, now has 83 daily departures from San Francisco to 35 destinations. Members of Alaska Mileage Plan can begin earning miles on Finnair starting today. Award redemption will commence later this year. Finnair Plus members can begin earning and redeeming points on Alaska Airlines starting today. “We are very excited to collaborate with Alaska Airlines on this new frequent flyer partnership,” said Juha Järvinen, chief commercial officer at Finnair. “Our customers travelling to and from the U.S. will greatly benefit from the extensive network both airlines have to offer.”  Known for its modern, Nordic-themed service, Finnair connects 18 cities in Asia and seven cities in North America to over 60 destinations in Europe. Finnair operates Airbus A330-300 aircraft on its U.S. routes.

Sweden Lists Entire Country on Airbnb

22 May 2017: Visit Sweden, Sweden’s official tourism board, has partnered with Airbnb to turn the entire country into an Airbnb listing: https://youtu.be/C6671CL5fFg. And the best part is - you don’t have to officially book accommodation because all publicly owned land is entirely free and accessible to everyone! Every lake is your infinity pool, every mountaintop your granite terrace, every meadow becomes a garden and every forest a pantry filled with mushrooms and berries. Feel free to take a morning jog or a bike ride across open fields or challenging mountain terrain starting right where you stand. Should you want an upgrade, you do not need to ask anyone, just find the places and the surroundings that suit you. “This is made possible thanks to a Swedish right guaranteed by the constitution - freedom to roam. This right enables the Swedish people to experience nature and enjoy the beautiful Swedish wildlife. In Sweden we have everything from high mountains to deep forests, from beautiful archipelagos to quiet meadows. Now, together with Airbnb, we welcome everyone to come to Sweden and, through freedom to roam, share our wonderful nature”, says Jenny Kaiser, USA Country Manager at Visit Sweden. Freedom to roam allows everyone and anyone to be free amidst Swedish nature with the right to access, walk, cycle or camp on any land, with private gardens and lands under cultivation being the only exception. The idea of free nature accessible to anyone is in the DNA of every Swede, but with great freedom comes responsibility. The general rule for spending time in nature is “do not disturb, do not destroy” – just like in any other home. “We are very excited to welcome Sweden on Airbnb, for everyone to explore. This partnership is a first of its kind collaboration between a tourism board and Airbnb. It is designed to promote Sweden as a destination through the power of the Airbnb community. We see Visit Sweden as our long term partner and are happy to join forces in promoting Sweden as a destination”, says James McClure, General Manager Northern Europe at Airbnb. The campaign is launched on 22 May, 2017.  To find out more about Sweden on Airbnb visit www.airbnb.com/SwedenCampaign video is available on https://youtu.be/C6671CL5fFg Contact info Visit Sweden Jenny Kaiser, President, Visit Sweden USAMobile: +1-917-297-8940Email: jenny.kaiser@visitsweden.com (jenny.kaiser@visitsweden.com%20) All press related material can be found at Visit Sweden's press room: http://news.cision.com/visit-sweden-usa. Contact info Airbnb press@airbnb.com About Visit Sweden Visit Sweden is a communications company promoting Sweden as a destination and as a brand. Our vision is to create a desire for Sweden, to encourage more foreign travelers to travel there. Visit Sweden forms partnerships with Swedish regions and other players in the Swedish tourism industry as well as non-tourism organizations to create marketing - and communication campaigns and raise the awareness and interest about Sweden as a tourist destination. Visit Sweden is present in 10 countries worldwide and combines local presence with market-wide communication. Visit Sweden has defined their target audience on all markets as The Global Traveler. Common to many in the target group is a curiosity about nature and lifestyle in Sweden. Visit Sweden is equally owned by the Swedish Government through the Ministry of Enterprise & Innovation and the Swedish Tourism Industry through Svensk Turism AB. About Airbnb Founded in 2008, Airbnb’s mission is to create a world where people can belong when they travel by being connected to local cultures and having unique travel experiences. Its community marketplace provides access to millions of unique accommodations from apartments and villas to castles and treehouses in more than 65,000 cities and 191 countries. With Experiences, Airbnb offers unprecedented access to local communities and interests, while Places lets people discover the hidden gems of a city as recommended by the people that live there. Airbnb is people powered and the easiest way to earn a little extra income from extra space in a home or from sharing passions, interests and cities. About the freedom to roam Sweden’s freedom to roam concept is based on a constitutional guarantee known as the Right of Public Access, which is a unique institution. The literal meaning of the Swedish term of the Right of Public Access, allemansrätten, is ‘everyman’s right’. It provides anyone living in or visiting Sweden the freedom to roam just about anywhere in the countryside as long as there is no disturbance or destruction of property or the environment. Many Swedes regard the Right of Public Access as part of a cultural heritage, sometimes even as a national symbol. Its origins go back in part to provincial laws and customs dating from the Middle Ages.

SpaceQuest places order for two advanced nanosatellite platforms from GomSpace

May 22, 2017 – GomSpace ApS (”GomSpace”) a subsidiary of GomSpace Group AB (publ) (the ”Company”) has entered a delivery contract with the American company SpaceQuest, Ltd. SpaceQuest, one of the pioneers and leaders in microsatellite technologies and solutions, has placed an order with GomSpace for the delivery of two advanced 3U nanosatellite platforms, associated software and payload components for a total amount of USD $325,000. The nanosatellite platforms will feature fully flight proven core subsystems as well as GomSpace’s state-of-the-art Software Defined Radio solutions. For more information, please contact:Niels Buus (CEO)Tel: +45 40 31 55 57Email: nbu @ gomspace.com About Gomspace Group AB The Company’s business operations are mainly conducted through the wholly-owned Danish subsidiary, GomSpace ApS, with operational office in Aalborg, Denmark. GomSpace is a space company with a mission to be engaged in the global market for space systems and services by introducing new products, i.e. components, platforms and systems based on innovation within professional nanosatellites. The Company is listed on the Nasdaq First North Premier exchange under the ticker GOMX. FNCA Sweden AB is the Company’s Certified Adviser. For more information, please visit our website on www.gomspace.com. About SpaceQuest, Ltd. SpaceQuest was an early innovator of microsatellites and today is a leading developer of microsatellites and advanced satellite technologies for government, university and commercial customers. It specializes in the design, development, testing and manufacture of spacecraft as well as space and ground components for operation with low-Earth orbiting satellites. Since its inception, SpaceQuest has built and launched 18 satellites, manufactured and delivered hundreds of satellite components for dozens of customers, and helped pioneer the collection of global AIS data from space. Miscellaneous  +-----------------------------------------------------------------------------+|This information is information that GomSpace is obliged to make public ||pursuant to the EU Market Abuse Regulation. The information was submitted for||publication, through the agency of the contact person set out above, 15.:30 ||CET on May 22, 2017. |+-----------------------------------------------------------------------------+

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the Managing Director were discharged from liability for the financial year 2016. The Meeting resolved to allocate the result in accordance with the proposal of the Board of Directors in the Annual Report. In accordance with the proposal by the Nomination Committee (i) Dennis Stripe, Saeid Esmaeilzadeh, Wilder Fulford, Christian Krüeger and Leif Ryd were re-elected as members of the Board of Directors, (ii) Laura Shunk was elected as new member of the Board of Directors, and (iii) Dennis Stripe was re-elected as Chairman of the Board of Directors. In accordance with the proposal by Nomination Committee, the Meeting resolved that total fees of SEK 1,100,000 are to be paid to the Board of Directors, of which SEK 400,000 to the Chairman of the Board of Directors, SEK 200,000 to each of Wilder Fulford and Laura Shunk and SEK 100,000 to each of Saeid Esmaeilzadeh, Leif Ryd and Christian Krüeger. No fees are to be paid for committee work. The registered accounting firm KPMG AB was re-elected as the auditor of the Company, with the authorised public accountant Duane Swanson as the auditor in charge. The auditors’ fee shall be paid upon approval of their invoice. The Meeting approved the Nomination Committee’s proposal for Nomination Committee and nomination procedure for the Annual General Meeting 2018. The Meeting approved the Board of Directors’ proposal regarding guidelines for remuneration to senior executives. In accordance with the proposal by the Board of Directors, the Meeting resolved on (i) adoption of an employee stock option and warrant programme, (ii) an issue of warrants of series 2017/2020(A), and (iii) an issue of warrants of series 2017/2020(B) and approval of transfers of warrants of series 2017/2020(B). The rationale for the employee stock option and warrant programme is to achieve optimum alignment of interests between the employees and the shareholders in the Company, to create conditions for retaining and recruiting competent personnel to the Episurf group and to drive performance among the employees. The employee stock option and warrant programme includes all employees in the group and comprises no more than 117,400 warrants of series 2017/2020(A) and no more than 513,700 employee stock options (which are hedged by an issue of the same number of warrants of series 2017/2020(B) to the subsidiary Episurf Operations AB). The warrants of series 2017/2020(A) shall be allocated to the participants in the programme for a price of SEK 0,95 (corresponding to the market value) in accordance with the following: (i) the acting CEO is entitled to subscribe for up to 15,000 warrants; (ii) the other four members of the senior management are entitled to subscribe for 8,000 warrants each; and (iii) the other 22 participants are entitled to subscribe for 3,200 warrants each. The employee stock options shall be allocated in accordance with the following: Each participant is proposed to be allotted, free of charge: (i) 6,000 employee stock options (except the acting CEO, who is allotted 10,000 employee stock options), plus (ii) 350 employee stock options per month he or she has been employed by the group, plus (iii) one employee stock options for each warrant subscribed for. Provided that the holder is still employed by the group at the exercise of the options, each employee stock option entitles the employee to purchase one share of series B in the Company during the period 1 June 2020 – 31 May 2021 for a price of SEK 8,55, corresponding to 130 per cent of the average volume weighted share price for the Company’s share of series B on Nasdaq Stockholm during the period from and including 15 May 2017 until and including 19 May 2017. Each warrants of series 2017/2020(A) entitles its holder to subscribe for one share of series B in the Company during the period 1 June 2020 – 31 May 2021 for a price of SEK 8,55. The programme implies that a maximum of 631,100 shares of series B may be issued, corresponding to a maximum dilution of 2.0 per cent of the share capital and 1.4 per cent of the votes in the Company. The employee stock options will be recorded as a personnel expense in the income statement during the vesting period. The total costs for the employee stock options are expected to amount to SEK 0.7 million during the term of the programme. Finally, the Meeting resolved to authorise the Board of Directors to, at one or several occasions until the next Annual General Meeting, resolve on new issues of shares. Episurf Medical AB (publ) The Board of Directors  For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical  Tel: +46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 19.30 CET on 22 May 2017.

BAKKAFROST: Operational EBIT of DKK 335 million for the first quarter of 2017

The Bakkafrost Group delivered a total operating EBIT of DKK 335.5 mil­lion in Q1 2017. Harvested volumes were 13.2 thousand tonnes gutted weight. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million. The farming segment made an operational EBIT of DKK 373.2 million. The salmon spot prices continued in Q1 2017 on a high level from 2016, which was positive for the farming segment. The VAP segment realized higher prices, but is not matched by the high spot prices, and therefore the VAP segment had negative margins in Q1 2017. The VAP segment made an operational EBIT of DKK -53.0 mil­lion. The EBITDA for the FOF segment was DKK 45.1 million. The total volumes harvested in Q1 2017 were 13.2 thousand tonnes gutted weight. Bakkafrost trans­ferred 1.4 million smolts in Q1 2017. In Q1 2017, Havsbrún sourced 106.6 thousand tonnes of raw material. The farming segment made an operational EBIT of DKK 373.2 million for Q1 2017, which corresponds to NOK 34.27 per kg. The VAP segment made an operational EBIT of DKK -53.0 million for Q1 2017. Although the sales prices in the VAP segment have increased, the VAP segment continued to have negative results, primarily due to the high salmon spot prices. The new VAP factory at Glyvrar started production in January 2017, and Q1 2017 was the first quarter when both the harvest operation and the VAP production operated in the combined VAP/harvest factory at Glyvrar. Simultaneously, the old VAP factories were closed. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million for Q1 2017, which corresponds to NOK 29.40 per kg. The FOF segment (fishmeal, oil and feed) made an operational EBITDA of DKK 45.1 million for Q1 2017. Commenting on the result, CEO Regin Jacobsen said: “The first quarter of 2017 was an eventful quarter for Bakkafrost in many ways. In January, Bakkafrost started the VAP production in the new combined harvest/VAP factory at Glyvrar, which was the last of three operations to start up at the premises at Glyvrar since 2014. The two previous are the packaging operation and the harvest operation, which started up in 2014 and 2016 respectively. There were challenges in the farming operation in this quarter, as ISA-virus was confirmed on one farming site. Since ISA suspicion arose in July 2016, Bakkafrost has monitored the development at the farming site closely together with the authorities. Timely action has been taken and all fish harvested immediately.” Bakkafrost’s farming site A-73 Hvannasund Norður has been under suspicion of pathogenic ISA-virus since July 2016. The suspicion rose anew in January 2017, and Bakkafrost decided to harvest the two cages, related to the suspicion. Medio March 2017, Bakkafrost decided to harvest the whole site early as a precautionary action. At the end of March 2017, pathogenic ISA-virus at farming site A-73 Hvanna-sund Norður was confirmed. Bakkafrost decided to accelerate the already started harvest. The harvest of farming site A-73 Hvannasund Norður ended on 12 April 2017, and the average size of the harvested fish was just below 3 kg gutted weight. The Bakkafrost Group’s net interest bearing debt amounted to DKK 458.6 million at the end of Q1 2017. Bakkafrost had undrawn credit facilities of approximately DKK 826.4 million at the end of Q1 2017 and the equity ratio was 65% at 31 March 2017. OUTLOOK Market The salmon market has for the last year or so been affected by decline in supply. The main factors behind this were the harmful algal bloom in Chile in February 2016 and the biological issues in Norway. The negative effect of the Chilean algal bloom on supply of salmon continued into Q1 2017. Expecta­tions are that global supply of Atlantic salmon will shift from reduced supply into growth of supply in Q2 2017. The latest update from Kontali Analyse estimates a global supply of Atlantic salmon to in­crease around 2% in 2017, compared to -6% in 2016. The market place is one of Bakkafrost’s most significant risk areas. Bakkafrost has a geographical and a market price approach. These approaches reduce the exposure to the market risk. To diversify the geographical market risk, Bakkafrost sells its products to all the largest salmon markets in the world, USA, the Far East, Europe and Russia. Farming The outlook for the farming segment is good. The estimates for harvesting volumes and smolt releases are dependent on the biological development. The biological situation is Bakkafrost’s most important risk area. The confirmed presence of patho­genic ISA-virus at farming site A-73 in March, draws attention to the importance of a high quality veter­inary system to reduce the biological risk. Harvest of the fish at farming site A-73 was finished on 12th April 2017, and the site is now in fallow. Bakkafrost focuses on biological risk continuously and has made several new investments and procedures to diminish this risk. The investments in producing larger smolts will gradually reduce the time needed in the fjords to farm the salmon. This is expected to reduce biological risk and increase the capacity. The capacity growth from this investment program will appear in harvested volumes gradually until 2021. Bakkafrost expects to harvest 53,500 tonnes gutted weight in 2017. Bakkafrost expects to release 11.5 million smolts in 2017, compared with 11.7 million smolts in 2016 and 11.3 million smolts released in 2015 – smolts released by Faroe Farming before becoming part of the Bakkafrost Group are included. The number of smolts released is a key element of predicting Bakka­frost’s future production. Sea lice is an area, which has demanded much effort and is a part of the biological risk. The new Faro­ese regulations on sea lice control, which aim at reducing the number of sea lice even further, is ex­pected to increase the operational costs for farming salmon in the Faroe Islands. Bakkafrost focuses on using non-chemical methods in treatments against sea lice. Bakkafrost’s live fish carrier M/S Hans á Bakka has carried out freshwater treatment against sea lice since Q4 2015. In Q4 2016, Bakkafrost invested in a service vessel, M/S Martin, which will primarily use lukewarm sea­water treatment against sea lice. M/S Martin started operation in Q1 2017. In addition to M/S Martin, Bakkafrost invested in another service vessel, M/S Róland, in Q1 2017. M/S Róland is equipped with the same system as M/S Martin and is expected to start operation in June/July 2017. Furthermore, Bakkafrost will increase the use of lumpfish in farming significantly in 2017. VAP (Value added products) Bakkafrost has signed contracts covering around 39% of the expected harvested volumes for the rest of 2017. VAP contracts are at fixed prices, based on the salmon forward prices at the time they are agreed and the expectations for the salmon spot price for the contract period. The contracts last for 6 to 12 months. The long-term strategy is selling around 40-50% of the harvested volumes of salmon as VAP products at fixed price contracts. Selling the products at fixed prices reduces the financial risk with fluctuating salmon prices. The market price for contracted VAP products follows a more stable pattern instead of short-term fluctuations as in the spot market. The price level on long-term contracts are on a higher level than ever before, there are, however, no indications that this price level should decrease significantly. FOF (Fishmeal, -oil and feed) The outlook for the production of fishmeal and fish oil is dependent on the availability of raw material. The ICES 2017 recommendation for blue whiting is 1,342 thousand tonnes, compared with 776 thou­sand tonnes in 2016. Recommendations for herring and mackerel quotas have increased as well. The forecast for production of fishmeal and fish oil is positive and will most likely increase due to higher quotas and better availability. The major market for Havsbrún´s fish feed is the local Faroese market including Bakkafrost’s internal use of fish feed. Havsbrún’s sales of fish feed in 2017 are expected to be at 85,000 tonnes. Investments In June 2016, Bakkafrost announced a five-year investment plan from 2016 to 2020. The total invest-ments for the period are DKK 2.2 billion, including maintenance CAPEX. Investments of around DKK 100 million in the two service vessels, M/S Martin and M/S Róland during 2017, are not included in the investment plan. The purpose of the investment plan is to continue to have one of the most cost conscious value chains in the farming industry, to carry out organic growth, increase flexibility and reduce the biological risk to meet the future consumers’ trends and to be more end-customer orientated. Bakkafrost aims at being self-supplied with smolts at a size of 500g each. The benefits are a shorter production time at sea as well as reduced biological risk. To reach this goal, approximately half of Bakkafrost’s total investments over the next five years will be in hatcheries. Both the harvest operation and the VAP production in the new harvest/VAP factory at Glyvrar are operating. The harvest operation started in the summer of 2016, and the VAP production started in Q1 2017. The old harvest factories in Klaksvík, Kollafjørður and Strendur are closed, as well as the old VAP factories in Fuglafjørður and Glyvrar. There are some extra costs during the start-up period, but the investment is expected to result in operational savings of DKK 70-90 million per year with gradual effect from 2017. Bakkafrost plans to increase the value of offcuts from salmon harvested and processed in the new harvest/-VAP factory. In 2017, Bakkafrost will invest in a new salmon meal and salmon oil plant, lo­cated in Fuglafjørður and operated by Havsbrún. The new salmon meal and salmon oil plant is ex­pected to start operation in late 2017 and is expected to have positive margins in 2018. The FOF seg­ment will also invest in a new feed line, which will increase the capacity of the feed production. Free cash flow from operations, existing financing facilities and partly new financing if advantageous will finance the investments. The dividend policy will be unchanged. Financial Improved market balances in the world market for salmon products and cost conscious production will likely improve the financial flexibility going forward. A high equity ratio together with Bakkafrost’s bank and bond financing makes Bakkafrost’s financial situation strong. This enables Bakkafrost to carry out its investment plans to further focus on strengthening the Group, M&A’s, organic growth oppor­tunities and fulfil its dividend policy in the future. Please find enclosed the Company’s Q1 2017 report and presentation. Contacts: Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) Gunnar Nielsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. About Bakkafrost: Bakkafrost is the largest salmon farmer in the Faroe Islands. The Group is fully integrated from feed production to smolt, farming, VAP and sales. The Group has production of fishmeal, fish oil and salmon feed in Fuglafjørður. The Group has primary processing in Glyvrar and Vágur, and secondary pro­cessing (VAP) in Glyvrar. The Group operates sea farming in Norðoyggjar, Eysturoy, Streymoy and Suðuroy. The headquarter is located in Glyvrar, and the company has 820 fulltime employees. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada or Japan. 2017-Q1 Presentation     Q1 2017 Condenced Interim Consolidated Accounts 

BerGenBio ASA: Results for the First Quarter 2017

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “During Q1 2017, BerGenBio has established a strong foundation from which to advance our development strategy for BGB324, a first-in-class, selective, oral Axl inhibitor, which has already delivered compelling clinical data in difficult-to-treat cancer patients. BerGenBio’s leadership in Axl inhibition ideally positions the company to address a major opportunity by developing new medicines to treat aggressive haematological and solid cancers, that evade the immune system, acquire resistance to cancer drugs and metastasise. The funds from our recent IPO will enable the company to complete our ongoing Phase II trials with BGB324 as a single agent and in combination with chemo- and immunotherapies” Operational Highlights Phase II clinical development program opened and enrolling · Lung cancer study in combination with erlotinib opened in first and second line setting. · Lung cancer study in combination with docetaxel opened & dosed first patients · Melanoma study in combination with targeted & I-O therapies opened and dosed first patients Collaborative agreement with Merck & Co (MSD) · Phase II combination trials (2) with MSD’s immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced lung cancer and triple negative breast cancer Board of Directors strengthened with appointment of Stein H. Annexstad as Chairman Registered wholly owned subsidiary BerGenBio Limited, to facilitate UK organization IPO launched and preparations made to list on Oslo Stock Exchange Grant from the Research Council · BerGenBio awarded a NOK 15.7 million grant from the Research Council of Norway under the program for user-managed innovation arena (BIA) Post-period events IPO achieved, raising NOK 400 million from new and existing investors to fund further clinical development of BGB324 and pipeline programs · BerGenBio shares began trading on OSE on 7 April 2017 under the ticker BGBIO. Presentations (2) at the American Association for Cancer Research (AACR) Annual Meeting 2017: · Presentation of a Phase II randomized clinical study with BGB324 in melanoma · Preclinical data of BGB324 in models of lung and breast cancer confirmed Axl to be a key factor in tumor resistance to cancer immune checkpoint inhibitors (CPIs) and a valid drug target. Data also showed that BGB324 treatment led to activation of the anti-tumor immune response. Financial Summary (NOK million) Q1 2017 Q1 2016 FY 2016 Operating revenues - - -Operating expenses 65.8 20.7 131.6Operating profit (loss) (65.8) (20.7) (131.6)Profit (loss) after tax (65.1) (20.3) (129.8) Basic and diluted earnings (loss) per share (NOK) (1.93) (75.21) (419.7)Cash position end of period 95.4 163.2 161.8 Presentation and Webcast Details A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Tjuvholmen The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished. The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day. -Ends- About BerGenBio ASA BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BGB324, is a selective, potent and orally available small molecule AXL inhibitor in Phase II clinical development in four major cancer indications. It is the only selective oral AXL inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with MSD. The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors including BGB149, anti-AXL monoclonal antibody. For further information, please visit: www.bergenbio.com   Contacts  Richard Godfrey CEO, BerGenBio ASA media@bergenbio.com +47 917 86 304 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Bydureon EXSCEL trial meets T2D safety objective

This announcement contains inside information 23 May 2017 07:00 BST BYDUREON EXSCEL TRIAL MEETS PRIMARY SAFETY OBJECTIVE IN TYPE-2 DIABETES PATIENTS AT WIDE RANGE OF CARDIOVASCULAR RISK Based on a composite measure of major adverse CV events (MACE), Bydureon did not increase cardiovascular (CV) risk and showed a consistent safety profile Fewer CV events were observed in the Bydureon arm, however, the efficacy objective of reduction in CV risk did not reach statistical significance AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE, a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes (T2D) at a wide range of CV risk. The EXSCEL trial met its primary safety objective of non-inferiority for MACE. These results address the US Food and Drug Administration (FDA) requirement that medicines to treat T2D are not associated with an increase in CV risk. Fewer CV events were observed in the Bydureon arm of the trial, however, the efficacy objective of a superior reduction in MACE did not reach statistical significance. Data were consistent with the known safety profile of Bydureon. Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: "These top-line results from the EXSCEL trial provide robust evidence of the cardiovascular safety profile of Bydureon across a wide range of patients with type-2 diabetes. Furthermore, the trial design and broad inclusion criteria of EXSCEL offer physicians relevant data applicable to clinical practice." The EXSCEL trial is the largest and most inclusive patient population of any CV outcomes trial of the glucagon-like peptide-1 (GLP-1) receptor agonist class conducted to date, having included more than 14,000 patients from 35 countries. A full evaluation of the EXSCEL data is ongoing. The results will be presented at the European Association for the Study of Diabetes (EASD) annual meeting on Thursday, 14 September 2017 in Lisbon, Portugal. About EXSCEL EXSCEL is a Phase IIIb/IV, double-blind, placebo-controlled, global CV outcomes trial conducted in 35 countries and enrolled more than 14,000 patients with type-2 diabetes with or without additional CV risk factors or prior CV events. Participants were randomised to receive exenatide once-weekly 2mg or matching placebo by subcutaneous injections. EXSCEL was run jointly by two academic research organisations - the Duke Clinical Research Institute (Durham, NC, US) and the University of Oxford Diabetes Trials Unit (Oxford, UK). About AstraZeneca in Diabetes AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes. As a main therapy area for the company, we are focusing our research and development efforts on diverse populations and patients with significant co-morbidities, such as cardiovascular disease, obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease. Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research programme. This commitment is advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination products to help more patients achieve treatment success earlier in their disease. About AstraZeneca in Cardiovascular & Metabolic Diseases (CVMD) Cardiovascular, renal and metabolic diseases are key areas of focus for AstraZeneca as part of the company's strategy for achieving scientific leadership and returning to growth. By collaborating across therapeutic disciplines within the CVMD therapy area, we are addressing the underlying disorders that drive CVMD risk, with the goal of reducing morbidity, mortality and organ damage through innovative therapies. Recognising the growing unmet needs and challenges faced by the millions of people worldwide living with these interrelated diseases, we are determined to understand how they interact and impact one another - and how they can be treated together to save more patients' lives. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. Media EnquiriesEsra Erkal-Paler UK/Global +44 203 749 5638Karen Birmingham  UK/Global  +44 203 749 5634 Rob Skelding  UK/Global  +44 203 749 5821 Jacob Lund  Sweden  +46 8 553 260 20 Michele Meixell  US  +1 302 885 2677  Investor RelationsThomas Kudsk Larsen +44 203 749 5712Craig Marks Finance, Fixed Income, M&A +44 7881 615 764Henry Wheeler Oncology +44 203 749 5797Mitchell Chan Oncology +1 240 477 3771Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970Nick Stone Respiratory +44 203 749 5716Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711US toll free +1 866 381 7277 Adrian Kemp Company Secretary, AstraZeneca PLC

Strategic partnership between Elekta and BESA to improve clinical workflows

Elekta Oy is the leading supplier of MEG technology with more than 100 MEG systems delivered and a 28-year track record of bringing leading solutions to the market. Founded in 1995, BESA (Brain Electrical Source Analysis) GmbH is a leading supplier of analytical software for MEG and electroencephalography (EEG) with 2,000 customers worldwide. Janne Huhtala, Head of Elekta’s Global MEG Business, says: “This partnership brings together BESA’s software development experience and Elekta’s MEG experts. Our sole focus will be to create a smooth, clinically appropriate software workflow built on the experience of – and in close collaboration with – our MEG users.” The announcement was made during the biennial meeting of the International Society for the Advancement of Clinical Magnetoencephalography (ISACM), in Sendai, Japan where both companies were present. To learn more about Elekta Neuromag, visit www.elekta.com/TRIUX.  # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European Time Raven Canzeri, Global Public Relations ManagerTel: +1 770 670 2524, e-mail: raven.canzeri@elekta.comTime zone: EST: Eastern Standard Time About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com About BESABESA GmbH was founded as MEGIS Software GmbH in 1995 by Dr. Michael Scherg. It is the leading company in the field of EEG / MEG analysis and a home base for highly skilled employees. Our products are designed based on 30 years’ experience in human brain research. BESA provides state-of-the-art scientific analysis tools covering the complete range of neurophysiological applications. We strive to bring our customers the latest methods for advanced EEG and MEG analysis in an optimized, user-friendly implementation. BESA GmbH is a privately-owned company headquartered in Germany. www.besa.de

Eltel’s Nomination Committee proposes Markku Moilanen as a new board member and revises its proposals for the AGM 2017 concerning the Board

Number of members of the Board of Directors Seven ordinary members of the Board of Directors with no deputy members. The remuneration for the Board of Directors The remuneration for the Board of Directors shall be EUR 531,200 to be allocated with EUR 175,000 to the Chairman, whereof EUR 75,000 is additional remuneration based on the extraordinary work load in the coming year, and EUR 49,500, whereof EUR 16,500 is an additional compensation based on the extraordinary work load in the coming year, to each six other members of the Board of Directors. Further, it is proposed that EUR 10,000 is paid to the chairman of the audit committee and EUR 8,200 to each of the members of the Audit Committee and the Remuneration Committee. The election of members of the Board of Directors For the period until the next Annual General Meeting has been held, the following members of the Board of Directors shall be re-elected for the period until the end of the next Annual General Meeting: Ulf Lundahl and Gunilla Fransson; and Ulf Mattsson, Håkan Dahlström, Hans von Uthman, Mikael Moll and Markku Moilanen, for the same period, shall be elected as new members of the Board of Directors; and that Ulf Mattsson is proposed to be elected as new Chairman of the Board of Directors. Markku Moilanen, born 1961, currently serves as Executive Director at Ramboll Group, COO of Northern Europe and globally responsible of Operational Excellence. Previous positions include Managing Director of Ramboll Finland, Vice President, Customer Services at Fortum and Sales Director at SAS Institute in Finland. Markku holds a D.Sc. (Eng.) from Helsinki University of Technology. Markku Moilanen does not own any shares in Eltel nor does any closely associated persons of him. Detailed information about all persons proposed to be elected as members of the Board of Directors may be found on Eltel’s website, www.eltelgroup.com. The Nomination Committee considers that Markku Moilanen is independent from the company and its management and from the company´s major shareholders. The Nomination Committee’s reasoned statement The Nomination Committee’s reasoned statement is available on the Company’s website, www.eltelgroup.com Stockholm, 23 May 2017 The Nomination Committee of Eltel AB (publ) For further information: Ingela Ulfves VP – Investor Relations and Group Communications Tel: +358 40 311 3009, ingela.ulfves@eltelnetworks.com  Henrik Sundell General Counsel Tel: +46 76 633 5220, henrik.sundell@eltelnetworks.se )  About Eltel Eltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 9,500. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

Magnolia Bostad signs agreement to acquire two properties in Huddinge

The acquisition is covered by the framework agreement signed by Magnolia Bostad in November 2016 with Slättö. With the acquisition, Magnolia Bostad has signed agreements for all projects covered by the framework agreement. In total, the framework agreement comprises 13 residential projects, to be developed and sold to Slättö. The seller is Spendrups and the acquisition, which comprises about 74,000 sq.m. of land, made thourgh company transfers with access at approved local plan. The purchase price is determined based on the size of the building right in the local plan. Program start for local plan is preliminary in the third quarter of 2017. Vårby Bryggor will be develop into the first marine district in Huddinge municipality and is one of the larger private development areas in the municipality. The area is located near Vårby Strandbad and Gömmaren's nature reserve with good communications within walking distance to two subway stations as well as the planned Tramway south. Magnolia Bostad's ambition is to develop a new attractive lakefront district. The vision is to develop an area with varied forms of beachfront housing in mixed tenure, residential care apartments and possibly a hotel. The area will be developed into a sustainable and vibrant neighborhood with green spaces and social venues. With the seafront location, there is potential to further improve communications to the area through, for example, new ferry connections to Stockholm. Legal adviser to Magnolia Bostad was Wigge & Partners Partners and DLA Piper Sweden AB has acted as legal adviser to the seller Spendrups. The deal was communicated by Cushman & Wakefield. "Huddinge municipality is very pleased that the property is being acquired by a residential developer. This is a great residential location close to Lake Mälaren with shopping in Kungens kurva and development of office areas in Flemingsberg nearby. says Malin Danielsson (L) Municipal Council for Social Affairs. For more information, please contact:Erik Rune, VP & Head of Business Development+46 73-399 40 30, erik.rune@magnoliabostad.se  Mikaela Senator, Investor Relations Manager+46 70-775 57 57, mikaela.senator@magnoliabostad.se  Magnolia Bostad develops efficient, attractive and functional residential properties, including rental apartments, tenant-owned apartments and hotels, in attractive locations primarily in Sweden’s growth areas. Our work is based on a holistic approach where the operations are conducted in a manner that promotes long-term, sustainable urban development. Magnolia Bostad's share (MAG) is listed on Nasdaq First North Premier. Erik Penser Bank is the Certified Adviser for the Company. More information is available at www.magnoliabostad.se 

Appointment of new CEO of Hunter Group ASA, new chairman of Dwellop AS and a related party transaction

The board of directors of Hunter Group ASA ("Hunter Group" or the "Company") has appointed Mr. Vegard Urnes as new interim Chief Executive Officer ("CEO") of Hunter Group. To this effect, the Company has entered into a consultancy agreement with Middelborg AS, where Mr. Urnes is employed as Investment Manager. His employment as CEO in Hunter Group takes effect immediately. Mr. Urnes has over 15 years of experience from corporate finance, with main focus on the oil service sector. Mr. Urnes has previously worked with corporate finance at Goldman Sachs, ProCorp and NRP Securities, before he founded Navis Finance in 2013, a M&A boutique with focus on alternative capital to the oil service and shipping sectors. Mr. Urnes holds a four year programme in economics and business administration consisting of three years at bachelor/undergraduate level and one year at master/graduate level (“Siv Øk”) from the Norwegian School of Management (BI) and is a Certified European Financial Analyst from the Norwegian School of Economics (NHH). Further, the Company has entered into a consultancy agreement with Mr. Eirik Bergsvik where Mr. Bergsvik shall provide the Company with general assistance related to business development and related commercial aspects related to the wholly owned subsidiary Dwellop AS as well as other parts of the Company. Mr. Bergsvik will also take on the position as chairman of the board of directors of Dwellop AS. Mr. Bergsvik has held a number of leading positions within the oil service industry, most recently as CEO of Interwell AS (2011 – 2016), board member at MHWirth and as Managing Director of National Oilwell Varco Norway AS (2006 – 2011).   The Company has further entered into a consultancy agreement with Middelborg AS, pursuant to which Mr. Kristian Gjertsen Lundkvist shall act as transaction advisor to the Company. The consultancy agreement has been entered into at market terms, with inter alia a success fee payable for transactions resulting from Mr. Lundkvist's services. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Oslo, 23 May 2017

Director and Management share purchases and Orderly Market Agreements

Share Purchases Adam Graham, the Group’s CEO, has acquired 300,000 ordinary shares in the Company (“Shares”) at €0.75 per Share for a total value of €225,000 in an off market transaction with another shareholder.  Following this acquisition Adam Graham’s total shareholding in the Company is 383,480 Shares, representing 1.2% of the Company’s issued share capital. Additionally, the following people who discharge managerial responsibilities in the Company (PDMR) have recently purchased shares in the Company: +-------+-------------+------------+--------+----------------------+|Name of|Position |Previous |Shares |Resultant Shareholding||Insider| |shareholding|acquired| || | |(Inc. PCA) | | |+-------+-------------+------------+--------+----------------------+|Pietro |PR and Social|153,526 |33,796 |187,322 ||Ranieri|Media | | | |+-------+-------------+------------+--------+----------------------+|Edward |Digital Lead |829,385 |2,350 |831,735 ||Sedgley|Generation | | | || |Agency | | | |+-------+-------------+------------+--------+----------------------+|Laurent|Social Media |851,673 |34,500 |886,173 ||Verrier|Marketing | | | |+-------+-------------+------------+--------+----------------------+ Orderly Market Agreement Shareholders holding 14,704,233 Shares in the Company, representing 46.76% of the Company’s issued share capital have now entered into the Orderly Market Agreement with the Company. The Shares subject to the Orderly Market Agreement include those issued to the original four founding agencies and Shares issued by the Company since IPO in consideration for subsequent acquisitions.  The Orderly Market Agreement commits the relevant shareholders to not dispose of any of their (and their PCAs) restricted Shares other than through the Orderly Market Agreement via the Company’s brokers for a period of three years from the date of signing. This information is information that The Marketing Group plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00am (CET) on 23 of May 2017.

Summa Equity builds platform for big-data enabled businesses

Summa Equity has invested in Swedish IVBAR Institute AB, Norwegian Documaster AS and UK-based Qlearsite Ltd. All three companies are early actors with leading solutions within different areas of big data solutions. Christian Melby, Partner at Summa Equity said: “The field of data analytics is growing exponentially. Niche markets are developing solutions tailored to the specific needs of businesses and organisations. IVBAR, Documaster and Qlearsite are all pioneers within their respective fields and have succeeded in developing technically sophisticated solutions with strong value propositions for users. We have closely followed the companies’ rapid market traction, the positive feedback received from customers and how the products have proven to be very solid.” Summa Equity is focused on helping Summa Digital companies in their next phase of development, with funding and support to scale up the businesses for broader roll-out and growth acceleration. Tommi Unkuri, Partner at Summa Equity, said: “The joint big data platform creates good conditions for synergies in for example go-to-market and development processes. These will be important growth enablers and accelerators.” IVBAR is a Swedish digital health company that has developed a big data analytics platform, ERA Vision, that enables improved management of healthcare through a focus on patient value. The platform improves transparency and provides unique levels of insight into both health outcomes and resource allocation, and is useful for both payors and providers of healthcare. IVBAR’s solutions have been developed in collaboration with both public and private partners, and the company has succeeded in consolidating vast amounts of highly fragmented healthcare data, enabling a level of insight previously unseen in the system. ERA Vision is used for advanced benchmarking, performance monitoring and calculation of reimbursement. Tommi Unkuri, continued: “IVBAR addresses fundamentally important topics in the healthcare sector and we believe that IVBAR will have a strong positive contribution to its customers and to patients. IVBAR’s solutions are highly scalable across countries, and the underlying challenges are similar in all healthcare systems. IVBAR has a unique position to provide solutions, based on close collaborations with public health providers in Sweden, its in-depth knowledge of the healthcare system, and a unique digital platform.” Documaster is a Norwegian digital record management company with core competence on digitization, information management and cloud-based archiving of valuable data. The company has developed a unique technology that addresses an increasing need for efficient and compliant archiving, driven by the rapid growth in digital documentation as well as an increased regulatory focus on record management. The solutions enable organisations to capture, process and preserve data in one single application, where it can easily and instantly be accessed through user-friendly retrieval and search functionality, whilst catering to relevant compliance requirements. The company offers a system agnostic archiving core that is compliant with EU and local regulations. Christian Melby, said: “Digital documentation is growing at an exponential rate and is rapidly phasing out physical documentation, leaving companies with out-dated, underperforming systems for record management. This is a growing headache for companies and institutions worldwide, and put them at risk of failure to meet regulatory standards. With Documaster’s solutions, organisations are able to regain control of their data. Documaster’s impressive technologies help customers to decommission legacy systems, digitalize paper documents, and gather all records into one application that is user friendly and quick to implement.” Qlearsite is an early actor in the rapidly growing field of people analytics for human resource management, based in the United Kingdom. The company has developed a technology that is specifically designed to analyse and make predictions about the behaviour of people in a workforce, using both structured and unstructured data. The product suite ranges across data connection and reporting, predictive analysis, and survey analytics, to create a complete toolbox for impactful analysis. The company defines their approach as Organisational Science, using intelligent analytics technologies with data generated by employees to enable corporations to understand the culture within their organisation and get important insights about how to get the best out of their talent base. Christian Melby continued: “Hiring the right people and making them thrive is a key value driver and crucial for the performance of any business. Companies worldwide are becoming increasingly aware of this strong connection between commercial success and proper management of employees, and thereby the value potential in being able to perform proper analysis on HR data. Qlearsite is at the forefront of this movement with their Organisational Science approach, helping companies to get a deep understanding of what influences their organisation, its people and how to improve performance. Their state of the art solution allows users to perform complete analysis that answers the questions of what, who and why and to make the right priorities in creating stronger organisations, thereby gaining competitive advantages and avoiding unnecessary costs.” Ends For more information, please contact: Christian Melby, Partner, Summa Equity, +47 (0)958 13 277, christian.melby@summaequity.com Tommi Unkuri, Partner, Summa Equity, +46 (0)70 508 1196, tommi.unkuri@summaequity.com Jonas Wohlin, IVBAR, +46 (0)708 55 37 00, jonas.wohlin@ivbar.com Pål Reinert Bredvei, CEO, Documaster, +47 (0)91 10 28 68, prb@documaster.no Peter Clark, Founder, Qlearsite, +44 (0)77 8866 5434, peter.clark@qlearsite.com Alex Borekull, Founder, Qlearsite, +44 (0)78 8779 1645, alex.borekull@qlearsite.com  About Summa Equity Summa Equity was formed in 2016 by partners with a shared vision of building a leading specialised private equity firm in the Nordic lower mid-market, positioned to capture the investment opportunity provided by the thematic megatrends expected to drive growth over the long term. The Firm focuses on sectors related to four megatrend driven themes: resource scarcity, energy efficiency, changing demographics and tech-enabled businesses. Summa Equity closed its first fund in February 2017 with commitments of SEK 4.5 billion.

TagMaster owned Balogh receives order from China & France

Press release Stockholm, Sweden, May 23, 2017 TagMaster, the leading supplier of advanced RFID products and ANPR cameras for vehicle identification and Rail solutions has, through its subsidiary Balogh SA, received orders from China & France for tramway project in China and for commuterline project in France . Balogh is one of the real pioneers in the RFID technology and was founded in 1958. Balogh today has offices for development and production in Paris, in Toulouse and in Normandie and works within the three RFID segments Rail, Access/Security (Traffic) and Industrial automation. The order comprises products used for ATP (Automatic Train Protection), i. e. equipment used to avoid collision caused by excessive speed or missed signal information and for train positioning. These products are part of the Balogh standard assortment but as often are adapted (NRE) for different projects and different customers and the order shows that Balogh has a strong product family among a number of rail applications. ”TagMaster has earlier expressed its enthusiasm for the Balogh acquisition and this order verify that our ambition, that together with Balogh become a stronger supplier within Rail solutions, is justified. We together get a wider product offering and we could together become one of the leading actors in train signaling and we will be able to take on bigger and more projects” says Jonas Svensson, CEO, TagMaster.  For further information please contact: Jonas Svensson, CEO, +46 8-6321950, jonas.svensson@tagmaster.com  About TagMaster TagMaster is an application driven technology company that designs and markets advanced identificationsystems and solutions based on radio & vision technology (RFID & ANPR) for demanding environments. Business areas include Traffic Solutions and Rail Solutions providing innovative mobility solutions, sold under the brands TagMaster, CitySync, Balogh & CA Traffic, in order to increase efficiency, security, convenience and to decrease environmental impact within Smart Cities. TagMaster has dedicated agencies in the US and in China and exports mainly to Europe, Middle East, Asia and North America via a global network of partners, systems integrators and distributors. TagMaster was founded in 1994 and has its headquarters in Stockholm. TagMaster is a public company and its shares are traded on First North stock exchange in Stockholm, Sweden.TagMasters certified advisor is Remium Nordic AB. For more information about TagMaster, please visit www.tagmaster.com

Ford Honors Bulten Joint Venture Company at 19th Annual World Excellence Awards

DEARBORN, Mich., May 23 2017 – BBB Services Ltd was recognized as a top-performing global supplier for Ford Motor Company at the 19th annual Ford World Excellence Awards. Fifty-four companies were selected from thousands of Ford global suppliers. BBB Services Ltd was presented with a Special Recognition Award by Hau Thai-Tang, Ford Motor Company group vice president, global purchasing. “We are extremely honored and proud to receive this award,” said Tommy Andersson President and CEO of Bulten and Chairman of BBB Services Ltd. “The Ford World Excellence Awards recognize the outstanding achievements of our top-performing global suppliers,” said Thai-Tang. “Suppliers like BBB Services Ltd are key to Ford’s continued success as we transform to an auto and mobility company.” Honorees were recognized for achieving the highest levels of global excellence in a variety of categories, including: · Primary Brand Pillars – quality, green, safe and smart · Aligned Business Framework principles focused on quality, value and innovation · Lincoln Luxury · Supplier Diversity Development For further information, please contact: Tommy Andersson, President and CEO of Bulten and Chairman of BBB Services LtdTel: + 46 (0)31-734 59 00 About Bulten Bulten is one of the leading suppliers of fasteners to the international automotive industry. The company’s product range includes everything from customer-specific standard products to customized special fasteners. The company also provides technical development, line-feeding, logistics, material and production expertise. Bulten offers a Full Service Provider concept or parts thereof. The company was founded in 1873, has some 1,300 employees in nine countries and head office in Gothenburg. The share (BULTEN) is listed on Nasdaq Stockholm. BBB Services Ltd is a majority owned joint venture company by Bulten. Read more at www.bulten.com About Ford Motor Company Ford Motor Company  is a global automotive and mobility company based in Dearborn, Michigan. With about 202,000 employees and 62 plants worldwide, the company’s core business includes designing, manufacturing, marketing and servicing a full line of Ford cars, trucks and SUVs, as well as Lincoln luxury vehicles. To expand its business model, Ford is aggressively pursuing emerging opportunities with investments in electrification, autonomy and mobility. Ford provides financial services through Ford Motor Credit Company. For more information regarding Ford and its products and services, please visit www.corporate.ford.com.

Atlas Copco to launch consent solicitation to certain noteholders

Consent solicitation Atlas Copco intends to announce an invitation to holders of notes issued under its Euro Medium Term Note (EMTN) Program to consider waiving and amending certain terms and conditions of the notes in connection with the announced potential split of the Group in 2018. Background On January 16, 2017, Atlas Copco’s Board of Directors announced that it will prepare a proposal to its Annual General Meeting in 2018 (expected to be held in April 2018) to split the Group into two companies: Atlas Copco, focused on industrial customers, and Epiroc, focused on mining and civil engineering customers. Atlas Copco is seeking to ensure there is no possibility of an event of default occurring or being deemed to occur in connection with or as a result of the potential split. Capital structure Atlas Copco’s policy historically, as illustrated by its net debt/EBITDA ratio over the last ten years, has been to have a capital structure which maintains investor, creditor and market confidence and supports the future development of the business. Assuming that the Annual General Meeting 2018 approves the split, the plan is to continue with the same policy for Atlas Copco following the split. The expectation is that the net indebtedness of the Atlas Copco Group will be allocated between Atlas Copco and Epiroc approximately corresponding to their respective profitability (operating profit and EBITDA) and cash flow metrics (operating cash flow). This is aimed at ensuring that Atlas Copco will continue to have a strong financial profile, consistent with the past. If the split is approved, Atlas Copco’s outstanding notes will remain with Atlas Copco and some other Group debt will be allocated to Epiroc. Selected illustrative financial information of Atlas Copco after the split In connection with the consent solicitation, Atlas Copco has prepared the following unaudited selected illustrative financial information of Atlas Copco after the split to provide additional information for the noteholders. The unaudited selected illustrative financial information of Atlas Copco after the split gives effect to the split as if it had been completed as described in the full selected illustrative financial information of Atlas Copco after the split, which is attached. · Revenues of BSEK 74.1 in 2016, BSEK 70.1 in 2015 and BSEK 20.6 in the first quarter of 2017 · EBITDA(*) (1) of BSEK 18.3 in 2016, corresponding to an EBITDA margin(*) of 24.7% · Operating profit(*) (2) of BSEK 15.3 in 2016 (BSEK 14.7 in 2015), corresponding to an operating profit margin(*) of 20.7% (21.0% in 2015) · Net cash from operating activities(*) (3) of BSEK 13.0 in 2016 · Cash flows from investments in PPE and intangible assets(*) (4) of BSEK -1.6 in 2016 · Total assets of BSEK 87.6 as at December 31, 2016 ___________ (*)        The indicated financial performance measures are not defined according to IFRS. These performance measures provide complementary information and are used to help investors as well as Atlas Copco’s management analyze Atlas Copco’s operations and facilitate an evaluation of the performance. Since not all companies calculate financial performance measures in the same manner, these are not always comparable with measures used by other companies. These financial performance measures should therefore not be regarded as a replacement for measures as defined according to IFRS. (1)        EBITDA – Earnings Before Interest, Taxes, Depreciation and Amortization – equals operating profit plus depreciation, impairment and amortization. (2)        Operating profit equals revenues less all costs related to operations, but excluding net financial items and income tax expense. (3)        Includes a non-recurring income tax payment amounting to BSEK 2.3 related to the European Commission’s decision on certain Belgian tax rulings. (4)        Cash flows from investments in PPE and intangible assets include investments in property, plant and equipment and intangible assets, but exclude the cash flows from goodwill, intangible assets and property, plant and equipment through acquisitions. For the avoidance of doubt, investments in rental equipment are not included in cash flows from investments in PPE and intangible assets as they are included in net cash from operating activities. The full selected illustrative financial information of Atlas Copco after the split is attached. Forward-looking statements Some statements herein are forward-looking and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially and adversely affected by other factors  such as the effect of economic conditions, exchange-rate and interest-rate movements, political risks, the impact of competing products and their pricing, product development, commercialization and technological difficulties, supply disturbances, and major customer credit losses. 

H&M Foundation pledges over $20 million to education, clean water and women´s empowerment

The new three-year partnerships with UNICEF (Education), WaterAid (Clean water) and CARE (Women’s economic empowerment) build on the achievements and learnings made in the previous Global Programs which ended in January 2017. With this new pledge, the total donation since 2014 to the Global Programs is 360 million Swedish krona ($41 million/€37 million). So far, over 100,000 children are reached with education, over 250,000 school children have access to clean water and toilets and 100,000 women are empowered to start or expand their businesses. In addition, dialogues with governments have resulted in more resources to education and implementation of clean water, improved hygiene and sanitation in some of the poorest parts of the world. Due to the success of these programs, a renewed three-year commitment is now made. “We’ve seen that our programs can make real change and that makes both the H&M Foundation and our partner organizations very eager to move into the next gear. With our insights from the first three years, we are well-equipped to create even more impact together in the years to come,“ says Diana Amini, Global Manager, H&M Foundation. To make even more impact, all three programs include a component to break new ground. UNICEF will develop a tool to highlight the relevance of Early Childhood Development efforts for tolerance, cooperation and respect to prevent conflicts and bring communities together. CARE will launch a pioneering Global Report on the economic and social value of investing in women’s enterprise development and WaterAid will share learnings and best practice on how to deliver long lasting access to water, sanitation and hygiene services. “There is a constant need for new partnerships and innovative solutions and the H&M Foundation will continue to be a catalyst for positive change for the planet, communities and people. It is a long-term commitment from my family and this work has just begun,” says Karl-Johan Persson, Board member, H&M Foundation and CEO H & M Hennes & Mauritz AB. In a recently launched Impact Report 2013-2016 , H&M Foundation has compiled all its efforts so far, and the progress is also described in a short film . Media contact: Malin Björne, PR & Communications Manager, H&M FoundationTelephone: 46 (0)70 796 39 75E-mail: malin.bjorne@hmfoundation.com (malin.bjorne@hm.com) About H&M Foundation The H&M Foundation is a non-profit global foundation, privately funded by the Stefan Persson family, founders and main owners of H&M. Its mission is to drive long lasting positive change and improve living conditions by investing in people, communities and innovative ideas. Through partnerships with organizations around the globe, the H&M Foundation drives change within four focus areas; Education, Water, Equality and Planet. In addition to this, the Foundation can also provide emergency relief. Since 2013, the Stefan Persson family has donated 1.1 billion Swedish krona (USD 154 million/EUR 123 million) to the Foundation. For more information, visit hmfoundation.com. NOTE TO EDITORS Global Program Goals 2017-2020 UNICEF · Reach 145,000 children, parents, teachers and influencers with Early Childhood Development programs, so that every child can have the best start in life. · Facilitate collaboration within national ministries in four countries to enable implementation of Early Childhood Development services. · Develop a tool to highlight the relevance of Early Childhood Development efforts for tolerance, cooperation and respect to prevent conflicts and bring communities together. WATERAID · Give 150,000 people access to water and sanitation services in some of the world’s poorest communities.  · Improve systems for delivering sustainable water, sanitation and hygiene services in four countries. · Launch a Global Report to share learnings and best practice on how to deliver long lasting access to water, sanitation and hygiene services. CARE · Empower 100,000 women entrepreneurs from low-income communities worldwide to develop and grow their business. · Showcase successful business models in 7 countries to inspire women to become entrepreneurs, ensuring they have the right conditions to succeed. · Launch a pioneering Global Report on the economic and social value of investing in women’s enterprise development. Quotes from organizations ”Nearly 250 million children under the age of five in developing countries are at risk of poor development. We rely on support from our partners to reach the most vulnerable and excluded children to help change their life paths. UNICEF is grateful to the H&M Foundation for its ongoing support helping to make sure babies and children experience the love, good nutrition, stimulation through play and early learning, and protection they need in the critical early moments,” says UNICEF Chief of Early Childhood Development Pia Britto. “Today, 900 children under five die every day from diahorrea caused by dirty water and poor sanitation. This is something WaterAid is passionate to change. With the funding from the H&M Foundation we will be able to transform the lives of some of the world’s poorest people by improving their wellbeing and living conditions - not only today but tomorrow and for many years to come. This will take us one step closer to our vision where everyone everywhere have safe water, adequate toilets and improved hygiene,” says Cecilia Chatterjee-Martinsen, Chief Executive WaterAid Sweden. “We now know that women from poor communities have the potential to become successful entrepreneurs and take control of their lives. Through our partnership with the H&M Foundation, we will support a further 100,000 women entrepreneurs across the globe, helping them from survival to success. It is fascinating to see how women gain power once they believe in themselves,” says Reintje van Haeringen, Director, CARE Nederland.

NeuroVive to continue NeuroSTAT® clinical development after positive outcome in preclinical and clinical TBI studies

The combined positive outcome of the results from the clinical phase IIa CHIC (Copenhagen Head Injury Cyclosporine) study, conducted at Rigshospitalet in Copenhagen, Denmark, and the preclinical studies, done in collaboration with the University of Pennsylvania (Penn), USA, have now convinced NeuroVive to proceed into the next stage of clinical development. The company has therefore decided to close the CHIC study in advance and focus its TBI project efforts on preparing for the next clinical study with NeuroSTAT for TBI. The results of the open label CHIC study show that appropriate dose-dependent concentration levels can be measured in the blood, and that NeuroSTAT reaches the target, the central nervous system (CNS). No unexpected safety signals were detected. Thus, the primary objective of CHIC to demonstrate safety and elucidate pharmacokinetics of NeuroSTAT at two different dose levels (5 and 10 mg/kg/day) in patients with severe TBI has been reached. A significantly reduced volume of brain injury (35% decrease) after NeuroSTAT treatment was observed in MRI scans in the experimental TBI studies done in collaboration with Penn. Furthermore, these studies displayed positive changes in brain energy metabolite levels and mitochondrial respiratory function, as well as decreased generation of reactive oxygen species. “The NeuroSTAT effects observed in our state-of-the art experimental model for TBI are very promising. Our collaborative approach on preclinical study design will set a completely novel standard in the development of new drugs in the field”, said Susan Margulies, PhD, Professor in the Department of Bioengineering at the University of Pennsylvania, US, and lead investigator for the preclinical studies. “The positive results are important milestones for the NeuroSTAT clinical development program. We now have the data we need to move forward to the next phase in the clinical development. We want to thank all site staff, caregivers, patients and families at Rigshospitalet in Copenhagen for their valuable contribution to this project. Also, we wish to thank the team at Penn for a very fruitful collaboration that has given very important scientific support to the NeuroSTAT clinical program”, said Erik Kinnman, CEO at NeuroVive. “With the decision to move forward with the TBI program, the company’s project portfolio have matured further and the approach of protecting the mitochondria in TBI with NeuroSTAT is validated by the new data. Importantly, we are about to take another step towards developing a medicine to patients with TBI, which is an area of high unmet medical need”, he continued. NeuroVive has initiated preparatory activities for the continued clinical development program. Next step is discussions with regulatory authorities in Europe and the US regarding the findings in the clinical and experimental studies, as well as the design of the next clinical study (Phase IIb proof of concept). Additionally, study preparations such as production of investigational medicinal product, approval of the clinical trial application, IND approval, ethics committee approval etc. need to be completed before study start. About the Phase IIa clinical study, CHIC at Rigshospitalet in Copenhagen The phase II CHIC (Copenhagen Head Injury Ciclosporin) study was an open label study. The primary objective with the study was to establish safety and to characterize the pharmacokinetic profile of two dosing regimens of NeuroSTAT in severe Traumatic Brain Injury (TBI) patients. In addition, exploratory measurements to evaluate the efficacy of NeuroSTAT at mitochondrial level, and study how NeuroSTAT affects various biochemical processes after a brain injury, are being processed Principal Investigator for the study is Jesper Kelsen, MD, PhD, Specialist in Neurosurgery, Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital. About the TBI experimental studies at the University of Pennsylvania (Penn) In collaboration with Penn, NeuroVive has evaluated the effect of NeuroSTAT in a non-clinical experimental TBI model. A total of three substudies have successfully been conducted and completed. Positive results from the first two substudies established the pharmacokinetic profile of NeuroSTAT in blood, CSF and brain in the disease model, and showed that NeuroSTAT dose-dependently crosses the blood-brain barrier. The third and final sub study evaluated several different efficacy parameters related to mitochondrial function and metabolism, as well as advanced translational brain imaging MR techniques important in the design of the next clinical study. Further analyses are ongoing and additional data will be presented at the 7th Annual Traumatic Brain Injury Conference in Washington, DC, US on 24-25 May and at the Annual National Neurotrauma Symposium, Neurotrauma 2017, in Snowbird, Utah, US, on 9-12 July 2017. About TBI Traumatic brain injury (TBI) is caused by external violence to the head resulting in immediate damage to nerve cells. The damage continues to worsen for several days after the trauma, which in many cases has a significantly negative effect on the overall injury. At present, there are no approved treatments for the prevention of these secondary injuries. In the US, some 2.2 million people are affected annually, causing more than 50,000 deaths and 280,000 hospitalizations. The direct and indirect costs associated with TBI are an estimated USD 60 billion, and a large number of patients suffer moderate to severe functional disabilities requiring intensive care and various forms of support (www.nih.gov). The aim is that better preventive therapies for secondary brain damage, such as NeuroSTAT, will lead to higher survival rates, and significantly improve quality of life and neurological function of patients post-TBI. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project entering clinical phase I (KL1333). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact:Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard)www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on 23 May 2017.

Catena Media acquires casino affiliate Newcasinos.com

Newcasinos.com  is a fast-growing casino affiliate, specialising in reviewing and rating new online casinos. The business was launched in 2015 with the aim to update casino players with the latest trends and news. New Casinos’ markets are mainly UK as well as Sweden and Norway and through its niche focus the acquisition will provide Catena Media with an opportunity for product segmentation. The acquired assets are expected to generate quarterly sales of about EUR 550.000 with an operating margin of around 80 percent. The underlying UK market is currently growing quickly, further strengthening Catena Media’s position in regulated markets. The transfer of the assets and payment is scheduled to take place no later than the 15thof July 2017. The purchase price amounts to an upfront payment of EUR 7.650.000, which is being paid as a cash consideration in conjunction with the transfer of the assets. In addition, there is an earn-out of maximum EUR 4.250.000, which is based on revenue performance over a period of 12 months. In a reasonably expected scenario with a total earn-out purchase price of EUR 3.25 million, the seller needs to generate revenue growth between 25 and 50 percent during the period. “Catena Media has been in the forefront of the consolidation in the affiliate market and wants to keep a leading role. The company is predominantly focusing on larger assets since we are well positioned to capitalize on our size and growth. With this acquisition we are acquiring another successful online casino affiliate to complement and strengthen our portfolio. The sellers have demonstrated a solid growth and an interesting content offering. This is fully in line with our strategy of partly growing through acquisitions and continuing our solid growth story”, says Robert Andersson, CEO of Catena Media. For further information, please contact:   Robert Andersson, CEO Phone: +356 770 329 28 E-mail: robert@catenamedia.comwww.catenamedia.com  The information was submitted for publication, through the agency of the contact person set out above on May 23, 2017 at 09.00 CET About Catena Media  Catena Media is a fast-growing online performance marketing and lead generation company within iGaming with portals like AskGamblers  and RightCasino . The Group has established a leading market position through strong organic growth and acquisitions in its core markets. Catena Media was listed on Nasdaq Stockholm First North Premier in February 2016. By the end of 2016, the company’s revenues reached more than EUR 40 million on a yearly basis. The Group was founded in 2012 and has today about 230 employees. The Group Head Office is situated in Malta. The company’s certified advisor is Avanza. About Newcasinos.com Please visit:www.newcasinos.com/online-2017/www.new-casinos.uk/online-2017/

STRAX:INTERIM REPORT NO 1 FOR THE FINANCIAL YEAR 2017

· The Group’s sales for the period January 1 – March 31, 2017, amounted to MEUR 20.3 (20.2), gross margin amounted to 27.0 (23.9) percent. The Q1 2017 report is the first in which STRAX reports in EUR following a decision at an EGM held on December 22, 2016 to change the reporting currency from SEK to EUR. · The Group’s result for the period January 1 – March 31, 2017, amounted to MEUR 0.0 (0,1) corresponding to EUR 0.00 (0.00) per share. Equity as at March 31, 2017 amounted to MEUR 18.2 (11.1) corresponding to EUR 0.15 (0.09) per share. · Trailing 12 months’ revenues Q1 2017 amounted to MEUR 92.0 (83.4). The scalable growth model shows greater increase in profitability in relation to growth of revenues, EBITDA on a trailing 12 month basis amounted to MEUR 8.3 (3.9). · During the period, STRAX signed an exclusive contract with Tessco Technologies for STRAX proprietary brands in the US. STRAX won a multi-tiered tender with mobilcom-debitel in Germany to exclusively supply all sales channels with mobile accessories and connected devices, and Orange won GSMA GLOMO Awards at Mobile World Congress VR1 in the category of Best Mobile Wearable Technology with a VR headset developed in cooperation with STRAX.  · After the end of the period STRAX launched its first Vodafone branded protection range for three Vodafone devices brought to the market in Q2 and rolled out the mobilcom-debitel accessories offering. ”The year got off to a mixed start amid slowdown in retail and smartphone sales in most global markets, and focus has been on growing our presence in North America and the Middle East, whilst retaining market share in Western Europe. Gear4 and Urbanista continue to perform well across all our markets and are contributing to both growth and profitability”.                                                                                                                                                 Gudmundur Palmason, CEO  For further information please contact Gudmundur Palmason, CEO, Strax AB, +46 8 545 01750 This information is information that Strax AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:55 CET on May 23 2017.

Axactor AB - Completed Private Placement

Oslo, 23 May 2017 - The Board of Directors of Axactor AB (Axactor or the Company) has decided to issue 50 million new shares through a private placement (the Private Placement), raising total gross proceeds to the Company of approximately NOK 107.50 million. The shares are issued at a price of NOK 2.15 per share, which is equal to the closing price on May 22, 2017.  The Private Placement was based on strong interest from high quality institutional investors. These investors both support the Company today through the share-issue, but also potentially longer-term as the Company pursues strategic growth initiatives. Axactor has experienced a high deal flow in the market lately and also noticed a recent increase in size of portfolio opportunities, highlighting the need to be well-funded and supported by strong shareholders. The net proceeds from the Private Placement will be used for acquisitions of non-performing loan portfolios in existing geographies, as well as for general corporate purposes. Notification of allotment will be sent to the applicants by Carnegie (as the Manager) on or about 23 May, 2017. The new shares will be issued under the Company's existing authority to issue shares, adopted by the annual general meeting in 2016. Following the registration of the new share capital, the Company will have 1,276,488,769 shares outstanding and a total share capital outstanding of EUR 66,814,382.05. The share issuance was carried out as a private placement to secure completion of a transaction at a time when specific interest surfaced in the market and in order to complete a transaction without the significant discount typically seen in rights issues. Additionally, Axactor recognizes the benefit in further developing the Company's shareholder base. As a consequence of the private placement structure, the shareholders' preferential rights were deviated from. After due considerations, the Board of Directors of the Company is of the opinion that the Private Placement is in the best interest of the Company and its shareholders. The Board of Directors has taken into consideration, among other things, the fact that the Private Placement will further strengthen Axactor's financial position and support the Company in its continued pursuit of growth opportunities, that the Private Placement only constitutes 4.08% of the issued and outstanding shares in the Company, and the fact that the subscription price is equal to the current market price of the shares. The Board of Directors is of the opinion that there are sufficient reasons to deviate from the shareholders' pre-emption right to subscribe for the new shares. Carnegie acted as financial adviser to the Company in connection with the Private Placement. For further information, contact: Endre Rangnes Chief Executive Officer Mail: endre.rangnes@axactor.com Tel: + 46 8 402 28 00 Cell Phone: +47 48 22 11 11 Geir Johansen Chief Financial Officer Mail: geir.johansen@axactor.com Cell Phone: +47 477 10 451 Important information: The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Manager is acting for the Company and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release. Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. The information opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

Peter Dahlgren new CEO of Nordnet

- The financial industry has to adjust to rapid technological development, more regulations and increasingly aware customers. Nordnet is perfectly positioned in that environment. With 600,000 customers and 240 billion in savings capital, we have a good base to stand on. At the same time, we have the optimal size to be agile and respond quickly to changing customer behavior, says Peter Dahlgren.  Nordnet has recently been bought out from the stock exchange and received a new board in February. Now the new CEO is also in place.  - This is a good and strong recruitment. Peter Dahlgren has broad experience from the financial industry. He is one of the most knowledgeable persons in savings and pension in the country, and has driven the development towards new digital customer offerings. His mission is to take Nordnet to the next level, says Hans Larsson, Chairman of Nordnet.  Peter Dahlgren was born in 1972, and since his employment started in SEB 2008, he has worked as Investment manager, head of Institutional Clients, responsible for the savings organization, and most recently as Head of the business area Life, Pension & Asset Management. Prior to that he has worked for Nordea, Skandia Liv and the state-owned pension fund AP7.  In October last year, Nordic Capital Fund VIII ("Nordic Capital") and Öhmangruppen, through NNB Intressenter, acquired all outstanding shares in Nordnet. At an extraordinary meeting in February, a new board was elected. In addition to Hans Larsson, the board consists of Tom Dinkelspiel and Jan Dinkelspiel from Öhmangruppen, Christian Frick, Partner, NC Advisory AB, Adviser to Nordic Capitals Funds, Christopher Ekdahl, Director, NC Advisory AB, Nordic Capitals Adviser Funds and Blocket founder Pierre Siri.  - It is a strength to work in a private environment with strong and committed owners. We will now build the best customer experience in the world within investment and savings. In order to do that, we have to be even better at understanding our customers' needs and have a higher pace in turning them into concrete deliveries – that goes for interfaces, products as well as new services, says Peter Dahlgren. 

iLOQ has appointed Heikki Hiltunen as the new CEO and President as of 1 August 2017

iLOQ, the innovative and fast growing digital access management company, has appointed Heikki Hiltunen as the new CEO and President as of 1 August 2017. Hiltunen has a long and successful background in industrial automation in a global business environment. Currently he is the Senior Vice President responsible for Sales, Marketing and After Market Services at Danfoss Drives Segment. Prior to Danfoss, Hiltunen was the Executive Vice President, Market Operations at Vacon Plc. -I am proud and excited to join iLOQ team. I am 54 years old and I have been in the drives and industrial automatization business for 30 years. Now, I am excited to start a new chapter in a new role, and in a completely new type of business. iLOQ is not only about technology transformation. It also enables new business models and a new level of service within access management, Heikki Hiltunen says. Vice President Esa Myllylä has been acting as an interim CEO at iLOQ since March 2, 2017. He will continue as the Executive Vice President. The Former CEO and founder Mika Pukari continues as a Board member. -I am extremely happy to welcome Heikki to iLOQ team. His broad experience will be extremely valuable for us as we step up our growth pace, and it will allow me to focus on my duties as a member of the Board, Mika Pukari says. As all the infrastructure around buildings, also access management and locks are going through a fundamental transformation, where new digital technologies play an important role. iLOQ has uniquely solved a lot of problems to enable a truly digitalized access management. iLOQ is the first and the only electronic lock cylinder in the world that self-powers by harvesting electricity from key insertion. -I have personally known Heikki for a long time, and I am confident that he can lead iLOQ towards its ambitious growth targets, and into the truly global company that it deserves to be, iLOQ Chairman Veijo Karppinen summarizes. iLOQ was established in 2003. In 2016, its revenues totaled 33,7 MEUR (increase +46 % from 2015), and it has about 70 employees. iLOQ has received several awards for its products and technology including 2016 Detektor International Award for “Best Access Control product” and Deloitte technology FAST 50 Finland for “Fastest growing technology company in Finland”. -I love to work with technology in a global context. I feel that together with the iLOQ team we can build this into a truly global success story. I can’t wait to get going, Hiltunen says. Additional Information: · Heikki Hiltunen, +358 40 837 1609 or heikki.hiltunen(at)hotmail.com · Veijo Karppinen, +358 40 837 1210 or veijo.karppinen(at)vntm.com iLOQ in Brief iLOQ is a Finnish growth company that transforms mechanical locking into digital access management. iLOQ provides self-powered digital locking and access management that revolutionizes the locking industry, as digital cameras have transformed photography. iLOQ solutions are based on technologies developed and patented by us, that enable electronic locking without batteries or cables. iLOQ has its headquarters in Oulu, Finland and offices in Denmark, Germany, the Netherlands and Sweden. www.iLOQ.com, LinkedIn  Distribution: Main media in Finland and global trade media #buildings #construction #access management #locks

NetEnt sharpens its claws with release of latest title Copy Cats

The 5-reel, 3-row, 25-line (fixed) video slot features a clowder of crazy city kitties roaming the streets during the day, while being chased down the spooky dark alleys by spotlight at night. Copy Cats is packed with Free Spins, Bonus symbols, Wild substitutions, Stacked symbols, Stacked Wilds and a Copy Cats feature. NetEnt’s newest production features red, blue, pink, and golden kitties, which are brought to life by vibrant animations and a jazz-inspired soundtrack. Simon Hammon, Chief Product Officer of NetEnt, said: “The release of Copy Cats purr-fectly demonstrates the versatility and breadth of appeal offered by the NetEnt games portfolio. “The title is full of features, vibrant animations and an easy-listening soundtrack that we’re sure will leave players feline good. It’s certain to be a kitty classic.” For additional information please contact:Simon Hammon, Chief Product Officer NetEnt, Phone +356 21 311 621simon.hammon@netent.com Anna Romboli, Chief Communications Officer NetEnt, Phone +46 8 578 54 500anna.romboli@netent.com NetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by their cutting-edge platform. With innovation at its core, NetEnt is committed to helping customers stay ahead of the competition. NetEnt is listed on Nasdaq Stockholm (NET-B), employs 900 people and has offices in Stockholm, Malta, Kiev, Gothenburg, New Jersey, Krakow and Gibraltar. www.netent.com

Making biological drugs with spider silk protein

Surfactant revolutionised the care of preterm babies by reducing the surface tension in their pulmonary alveoli and allowing them to be inflated at the moment of birth. Curosurf, the most globally widespread drug, was developed by scientists at Karolinska Institutet in the 1970s and 1980s. The drug is produced by the isolation of proteins from pig lungs, a process that is expensive, complicated and potentially risky. Researchers at Karolinska Institutet and their colleagues from the University of Riga amongst other institutions, have now developed a surfactant drug that can be produced much more simply and cheaply using spider protein. “The manufacturing process is based on the method spiders use to keep their extremely easily aggregated proteins soluble for silk-spinning,” explains Professor Jan Johansson at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society. “We chose to produce lung surfactant protein C because it is probably the world’s most aggregation-inclined protein.” By applying this method, the researchers have managed to produce a range of potential biological drugs using the part of the spider protein that ensures that the proteins remain soluble, namely the N-terminal domain. “We had bacteria produce this part of the protein and then linked it to different protein drug candidates,” says docent Anna Rising at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society who co-led the study with Professor Johansson. The researchers also compared their synthetic lung surfactant with the biological analogue currently on the market and found it equally effective at reducing the surface tension in an animal model of neonate respiratory disorders. “Since this production method is much simpler and cheaper, it might one day be possible to use our synthetic lung surfactant to treat more lung diseases than just preterm babies,” adds Professor Johansson. “The method will also hopefully enable the production of other biological drugs.” The study was primarily financed by the Swedish Research Council and was performed in collaboration with the Italian pharmaceutical company Chiesi Farmaceutici. Publication: “Efficient protein production inspired by how spiders make silk”. Nina Kronqvist, Médoune Sarr, Anton Lindqvist, Kerstin Nordling, Martins Otikovs, Luca Venturi, Barbara Pioselli, Pasi Purhonen, Michael Landreh, Henrik Biverstål, Zigmantas Toleikis, Lisa Sjöberg, Carol V. Robinson, Nicola Pelizzi, Hans Jörnvall, Hans Hebert, Kristaps Jaudzems, Tore Curstedt, Anna Rising & Jan Johansson. Nature Communications, online 23 May 2017.

Invitation to Elekta’s year-end report and company update presentation

Presentations will start at 15:00 CET and will end at approximately 17:00 CET. Speakers at the event will include Richard Hausmann, Elekta’s President and CEO, Håkan Bergström, Elekta’s CFO, and Ioannis Panagiotelis, Elekta´s Chief Marketing Officer. Gustaf Salford, who will succeed Håkan Bergström as CFO, effective from July 1, 2017, will also be introduced at the event. The presentation will be held at IVA, Grev Turegatan 16, Stockholm. The doors open at 14:30 CET. It will also be possible to follow the presentation over the phone and as a live webcast. Details for this will be published on www.elekta.com/ir in advance of the meeting. Please confirm your participation by e-mail to frida.johansson@elekta.com. # # # For further information, please contact:Johan Andersson, Director Investor Relations, Elekta ABTel: +46 702 100 451, e-mail: johan.andersson@elekta.com Time zone: CET: Central European Time Tobias Bülow, Director Financial Communications, Elekta ABTel: +46 722 215 017, e-mail: tobias.bulow@elekta.com Time zone: CET: Central European Time Frida Johansson, Investor Relations, Elekta ABTel: +46 708 667 674, e-mail: frida.johansson@elekta.comTime zone: CET: Central European Time About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Lemminkäinen Infrahack competition winning solutions are agile and user-friendly

LEMMINKÄINEN CORPORATION           PRESS RELEASE         23.5.2017 AT 2 P.M.  LEMMINKÄINEN INFRAHACK COMPETITION WINNING SOLUTIONS ARE AGILE AND USER-FRIENDLY Three teams, Poimapper, PointScene and Siili, were chosen to take part in the pilot phase of the Lemminkäinen InfraHack innovation competition. The winning solutions have a strong link to Lemminkäinen’s strategy and targets. They also have the best potential for further development and eventually implementation in the businesses. The solutions will assist the planning and organisation of work, which will  benefit our customers with more efficient contract and project management.   The Poimapper team developed a solution for Lemminkäinen for speeding up the organisation of work and reporting in the different business segments. The innovation of the Siili team uses augmented reality in the planning of paving work. The solution of the PointScene team will ease project follow-up by using drones as tools.The Lemminkäinen InfraHack competition was held from 19–21 May 2017 in Helsinki, Finland. The goal was to find new ideas and agile solutions for improving information flow and operational efficiency in the Paving and Infra projects segments. Eight teams took part in the competition.   “InfraHack was a success and we got what we hoped for. Three agile and advanced ideas were chosen for further development as pilot projects,” says Robert Blumberg, Executive Vice President, Paving.   “Our jury chose the winning teams unanimously. Their solutions showed an deep understanding of the cornerstones of our businesses and the challenges presented. We are happy to have the chance to develop their ideas further,” says Harri Kailasalo, Executive Vice President, Infra projects.  The members of the InfraHack jury were:Sari Inkilä – EVP, Strategy and DevelopmentRobert Blumberg – EVP, PavingHarri Kailasalo – Executive Vice President, Infra projects Jaakko Kivi – SVP, Project and resource managementJarmo Rautanen – Director, Technical office, Paving Lemminkäinen organised the competition in cooperation with IndustryHack. For more information, please visit the IndustryHack website .    LEMMINKÄINEN CORPORATIONCorporate Communications  ADDITIONAL INFORMATION:Carolina AndersinDirector, Business Development, PavingTel. +358 2071 50306carolina.andersin@lemminkainen.com  Hannu RatamäkiDirector, Project Support, Infra projectsTel. +358 2071 59567hannu.ratamaki@lemminkainen.com  DISTRIBUTION:Key mediawww.lemminkainen.com   Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and the 4,700 professionals we employ, we build a sustainable society. In 2016, our net sales were EUR 1.7 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com   

Brighter represents data-driven health on state visits to Indonesia.

Brighter united with Swedish world-class companies such as Atlas Copco, Getinge, Elekta, IKEA, H&M, Ericsson, Scania, SKF and Volvo in a major venture in Indonesia. Brighter, which develops solutions for data-driven health, participates in Sweden's state visit to Indonesia from 22 to 24 May 2017. The company, which develops Actiste® - a service for insulin-treated diabetics and all relevant stakeholders in their care chain - already has extensive interests in Indonesia. The country today has the world's fourth largest population with its 255 million inhabitants. As early as 2030, however, Indonesia is estimated to have nearly 300 million inhabitants and be the world's seventh largest economy, with the middle class reaching 135 million people - more than any other developing country in the world. besides China and India. According to IDF statistics, about 10 million people in Indonesia suffer from diabetes today, and the annual increase is about 6%. Brighter signed an agreement in 2016 with one of Indonesia's leading mobile operators - Indosat Ooredoo - to launch Actiste on the Indonesian market in cooperation with Ericsson. Actiste will be marketed and sold as a service to both consumers and the healthcare sector. One of the key drivers behind Brighter's focus on Indonesia is its ongoing efforts in both private and public healthcare. In 2014, the Indonesian government launched a national health plan that includes diabetes treatment, digital services and medical devices like Actiste. "Now we can intensify work to help millions of diabetics who need to take daily blood glucose measurements and inject insulin. Our subscription-based service Actiste could not only make the daily routines easier, but also enable better follow-up and allow for improved possibilities to prioritize for healthcare professionals, supported by The Benefit Loop®. In this way, doctors have the potential to dramatically improve the results of treatment and reduce consequential complications such as amputations, dialysis and stroke, "says Trull Sjöstedt, Brighter's CEO and founder. Brighter is also a Shared Value Partner of Indonesia Mampu, contributing to the development of the first healthcare initiative, a program of works led by Palladium and the Indonesian government body National Team Secretariat for Accelerating Poverty Reduction (TNP2K). Indonesia Mampu’s partnership framework is aimed at alleviating poverty in Indonesia through a positive impact program based on four pillars of which one is healthcare. As part of this pillar there will be a focus on diabetes prevention and treatment where Brighter’s knowledge and technology will be an important component. An important part of Indonesia Mampus's approach is the private sector's participation, which means that the program selects the best-suited partners in different sectors in its work in diabetes, including nutrition and food, technology and data, as well as drugs and health, including Brighter with its Actiste® As the only diabetic aid. "We are proud of our commitment in Indonesia Mampu, which has received great attention in the country," said Truls Sjöstedt. The state visit  takes place from 22-24 May, and the delegation, with the king and the queen at the top, includes representatives from some thirty-six Swedish companies and institutions. The business delegation  is headed by Business Sweden. For more information, please contact:Truls Sjöstedt, CEO             Tel: +46 709 73 46 00             Email: truls.sjostedt@brighter.se  Henrik Norström, COO             Tel: +46 733 40 30 45             Email: henrik.norstrom@brighter.se About Brighter AB (publ) Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on  NASDAQOMX First North/BRIG  . Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50,  CorporateFinance@remium.com ,  www.remium.com .

Multiconsult ASA – Agreement with Hjellnes group

Multiconsult has signed a letter of intent with the board of directors in Hjellnes Holding AS for the acquisition of 100% of the shares in Hjellnes Consulting AS and Johs Holt AS. The settlement will be a combination of cash and Multiconsult shares. The closing date is planned by September 2017. Multiconsult ASA and the Hjellnes group have operated in the same industry for many years. The companies are familiar with each other through cooperation in many projects and the parties share a common view that they will have a strong strategic and cultural fit. Through the acquisition, Multiconsult will increase the multidisciplinary capacity and expertise within the core competencies in Buildings & Properties, Transportation and Water & Environment. The acquisition will also strengthen Multiconsult’s market position in the Greater Oslo area as well as within bridge construction, where Johs Holt AS is considered a market leader. Further, Multiconsult will increase its competitive advantage within health buildings and urban development in Norway, in line with its 3-2-1 GO strategy. Hjellnes Consult AS provides multidisciplinary engineering consulting services. The company has a solid expertise within buildings and properties, construction, infrastructure and environment. Johs Holt AS provides advisory services within all types of bridges and heavier structures.  At year-end 2016, the two companies had a combined total of 229 employees. For 2015, operating revenues were NOK 307.0 million, NOK 14.3 million in EBIT and NOK 117.2 million in assets. The acquisition is subject to approval by Hjellnes Holding AS’s ordinary general meeting on 30. May 2017. A final agreement is subject to a successful due diligence process and approvals from the board of directors in Multiconsult, board of directors in Hjellnes Holding AS and the Norwegian Competition Authority. Multiconsult will provide an update with further details once a share purchase agreement has been signed. For further information, please contact: Investor relations:               Mirza Koristovic, Head of Investor Relations               Phone: +47 93 87 05 25               E-mail: ir@multiconsult.no  Media:              Gaute Christensen, VP Communications              Phone: +47 911 70 188              E-mail: gaute.christensen@multiconsult.no   ABOUT MULTICONSULT ASAMulticonsult is a leading Norwegian multidisciplinary engineering consulting company, with more than 2 300 employees and 45 offices in Norway and abroad. The Company focuses on seven market areas: Buildings & Properties, Transport & Infrastructure, Energy, Oil & Gas, Industry, Environment & Natural resources and Architecture. The Company has an operating history that spans more than a century, with the inception of Norsk Vandbygningskontor in 1908. In 2015 Multiconsult completed more than 9 000 projects for approx. 4 000 different customers

Europe’s brewing industry to meet in Helsinki in June

Beer generates EUR 42 billion in tax revenue for European states every year – a sum equivalent to the entire tax revenue of Hungary. The brewing industry plays a key role in job creation, which is one of the main objectives of the EU’s growth strategy, Europe 2020. The livelihoods of more than two million people in Europe are dependent on the sale and production of beer. One job in a brewery indirectly creates 17 new jobs, that is, about one per cent of total employment in the EU: 2 jobs in agriculture and transportation, 2 in retail, and 13 in bars, pubs, cafés and restaurants that serve beer. “Breweries are proud of the significant role they play in the European economy. Breweries create jobs in the value chain and increase trade both within and outside the EU. A business-friendly policy will enable breweries to improve the general competitiveness of the European economy and promote sustainable growth,” says Pierre-Olivier Bergeron, Secretary General of the Brewers of Europe. Success in the brewing industry is heavily dependent on industrial and alcohol policy. Competitive taxation is a common requirement for all of Europe’s breweries. “Fair and reasonable taxation will benefit the entire value chain ‘from grain to glass’ and thereby the entire European economy. We need to ensure that taxation remains at a competitive level, so it doesn’t fuel cross-border trade in Europe,” says Bergeron. A strong beer boom throughout Europe Europe is currently experiencing a strong beer boom. The brewing industry is renewing itself and new breweries are being established. More than 3,000 new breweries have been established in Europe during the 2010s. Appreciation for beer has risen. “This marvellous Europe-wide trend can also be seen here in Finland. Appreciation for beer has risen, and beer is increasingly becoming an accompaniment for food. It’s important for society at large to take note of this, and vital that we eventually get the new Alcohol Act into force,” says Elina Ussa, Managing Director of the Federation of the Brewing and Soft Drinks Industry.  Beer is an important element of European identity – of its cultural traditions, society and economy. In recent years, beer production and its value chain have been experiencing growth in Europe. The Brewers of Europe is a non-profit umbrella organisation that promotes the united interests of about 7,500 breweries around Europe. The organisation was established in 1958 and unites national brewers’ associations from 29 European countries. The Federation of the Brewing and Soft Drinks Industry has been a member of the Brewers of Europe since 1995. The Brewers of Europe is also a founder member of the EU Alcohol and Health Forum.   Additional information and interview requests: The Brewers of Europe’s Pavlos Photiades (Chair), Pierre-Olivier Bergeron (Secretary General) and Jan de Grave (Communications Director) will give interviews to the media in Helsinki on 7–9 June. Interview requests: The Federation of the Brewing and Soft Drinks IndustryManaging Director Elina Ussa, tel. +358 (0)45 269 7711Communications Manager Outi Heikkinen, tel. +358 (0)50 370 8677 www.panimoliitto.fi, www.kohtuullisesti.fi, www.maljasuomelle.fiTwitter: @panimoliitto, Facebook: /panimoliitto, Instagram: @panimoliitto http://www.panimoliitto.fi/en/europes-brewing-industry-to-meet-in-helsinki-in-june/ The Federation of the Brewing and Soft Drinks Industry promotes the interests of producers of beer, cider, long drinks, soft drinks and mineral waters in Finland. Its members are Captol Invest Oy, Oy Hartwall Ab, Olvi Oyj, Red Bull Finland Oy, Saimaan Juomatehdas, and Oy Sinebrychoff Ab. The Federation of the Brewing and Soft Drinks Industry is a member of the Finnish Food and Drink Industries Federation.

Retransmitting: Senzime’s Interim report January – March 2017

Financial information first quarter 2017 · Net sales amounts to KSEK 0 (22) · Income after financial items amounts to KSEK -3,970 (-1,850). · Earnings per share before dilution amounts to SEK -0.11 kr (-0.12). · Cash and cash equivalents per March 31, 2017 equal SEK 3.8 million (11.9). · Number of shares per March 31, 2017 amounts to 36,172,643 (16,076,730). For further information, please contact: Jessica Roxhed, CFO Tel: +46 703-94 94 98, e-mail: jessica.roxhed@senzime.com  TO THE EDITORS   About Senzime   Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com  This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 23th 2017.

Resolutions at Senzime AB’s (publ) Annual General Meeting

A. Annual report and results The general meeting adopted the income statement and the balance sheet for the financial year 2016 and resolved, in accordance with the board of director’s proposal, that the result according to the approved income statement would be transferred on a new account. No dividend distribution. B. Discharge from liability The general meeting granted the board members of the board of directors and the managing director discharge from liability for the management of the company’s business for the financial year 2016. C. Board and auditor remuneration The general meeting resolved that the board should be remunerated as follows: SEK 100,000 to the chairman of the board and SEK 50,000 to each of the other board members. However, it was also resolved that no remuneration will be paid to a board member if he/she, during the financial year 2017, has received more than twice his/her remuneration as consultancy fees from the company. The general meeting further decided that auditor should be remunerated in accordance with approved invoices. D. Election of board and auditor The general meeting resolved that the board of directors shall consist of five directors and that no deputy directors shall be appointed. The general meeting resolved to, up until the conclusion of the next annual general meeting, re-elect Adam Dahlberg, Philip Siberg, Ulf Lindskog, Terry Cross (independent member) and Sorin Brull as board members. Philip Siberg was re-elected as the chairman of the board of directors. It was decided to re-elect PricewaterhouseCoopers AB, with Leonard Daun as chief auditor until the annual general meeting 2018. E. Nomination committee for the annual general meeting 2018 The general meeting resolved to adopt principles for the appointment of the nomination committee for the annual general meeting 2018. It was decided that the members of the Nomination Committee for the 2018 annual general meeting will be composed of representatives of the three largest shareholders together with the chairman of the board. F. Amendment of the articles of association The general meeting resolved to amend 4 § and 5 § of the articles of association whereby the limits for the number of shares and the share capital are amended. G. Authorization The general meeting resolved to authorize the board of directors – for the period up to the next annual general meeting – to issue shares, warrants and/or convertible instruments. The authorization may be used with deviation from the shareholders’ pre-emption rights and/or an issue in kind of by way of set-off (or otherwise on terms set out in the Swedish Companies Act). The authorization may be used to increase the company’s share capital with maximum SEK 495,730. All resolutions at the annual general meeting were adopted unanimously. For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com  ———————————— Senzime AB (publ) Board of directors TO THE EDITORS   About Senzime   Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.www.senzime.com 

Volvo Group Capital Markets Day

The presentations covered three main topics: Improving performance, Growing services and Leading in technology. During the Capital Markets Day, Volvo Construction Equipment’s Electric Site project with autonomous, electric-battery load carriers and the Volvo FMX self-driving truck that is currently being tested in operation in Boliden’s Kristineberg mine were demonstrated.In addition to Martin Lundstedt, presentations were also given by Jan Gurander, Deputy CE and CFO, Claes Nilsson, President Volvo Trucks, Dennis Slagle, President Mack Trucks, Bruno Blin, President Renault Trucks, Joachim Rosenberg, Chairman of UD Trucks, Jan Ohlsson, Executive Vice President Group Truck Operations, Martin Weissburg, President Volvo Construction Equipment, Martin Merrick, Senior Vice President Retail Development at Volvo Trucks, Lars Stenqvist, Executive Vice President Group Trucks Technology and by guest speaker Peter Burman, Program Manager at Boliden Mine Automation. A replay of the webcast and the presentation material will be available under Investor Relations on the Volvo Group’s web site www.volvogroup.com May 23, 2017  Journalists who would like further information, please contact Christer Johansson, Investor Relations, +46 31-66 13 34 For more stories from the Volvo Group, please visit www.volvogroup.com/press. The Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. The Volvo Group, which employs about 95,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2016 the Volvo Group’s sales amounted to about SEK 302 billion (EUR 31,9 billion). The Volvo Group is a publicly-held company headquartered in Göteborg, Sweden. Volvo shares are listed on Nasdaq Stockholm. For more information, please visit www.volvogroup.com. 

Minutes from Ordinary General Meeting on 23 May 2017

The ordinary general meeting in Nordic Mining ASA was held on Tuesday 23 May 2017. All items on the agenda were approved. The minutes from the Ordinary General Meeting is enclosed with this notice. For questions please contact CFO Lars K. Grøndahl, telephone +47 901 60 941. Oslo, 23 May 2017 Nordic Mining ASANordic Mining ASA (www.nordicmining.com)Nordic Mining ASA (“Nordic Mining” or “the Company”) is a resource company with focus on high-end industrial minerals and metals in Norway and internationally. The Company’s project portfolio is of high international standard and holds a significant economic potential. The Company’s assets are in the Nordic region.Through the subsidiary Nordic Rutile AS Nordic Mining is undertaking a large-scale project development at Engebøfjellet in Sogn and Fjordane where the Company has rights and permits to a substantial eclogite deposit with rutile and garnet. Permits for the project have been granted by the Norwegian government. Nordic Mining has rights for exploration and production of high-purity quartz in Kvinnherad in Hordaland and develops the project through its subsidiary Nordic Quartz AS. Nordic Mining’s associated company Keliber Oy in Finland plans to start mining of lithium bearing spodumene and production of lithium carbonate. Nordic Mining holds exploration rights on the Øksfjord Peninsula in Troms and Finnmark, where the Company has discovered a prospective area of sulphide mineralisation. Through the subsidiary Nordic Ocean Resources AS, Nordic Mining is exploring opportunities related to seabed mineral resources.Nordic Mining is listed on Oslo Axess with ticker symbol “NOM”.

Nordic Nanovector ASA – Results for First Quarter 2017

Oslo, Norway, 24 May 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the first quarter of 2017. A presentation by the company’s senior management team will take place today at 8:30 a.m. CET in Oslo - details below. Nordic Nanovector reported continued operational progress during the first quarter. The Phase 1/2 clinical trial with Betalutin® in relapsed indolent non-Hodgkin’s Lymphoma (iNHL) advanced according to schedule. Safety Review Committee (SRC)’s approval of continued clinical evaluation of 20 MBq/kg Betalutin® with 100 mg/m2 lilotomab enables the company to build a robust database of clinical data. Management is confident on plans to initiate the pivotal Phase 2 PARADIGME study in the second half of 2017. The first patient was dosed in a Phase 1 dose-escalation study of Betalutin® in relapsed refractory DLBCL. The company also made the decision to expand investigations of its ARC therapeutics with initial preparations underway for a Phase 2 combination study of Betalutin® and rituximab, and a Phase 1 study of Humalutin™, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC). Both studies are expected to start during the second half of 2017. Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical development programmes with Betalutin® in FL and now in DLBCL. We are also excited at the prospect of starting new clinical trials later in the year, which potentially could significantly expand the market opportunities for our novel ARCs.” Operational Highlights Q1 2017• Progress continues towards start of Phase 2 PARADIGME trial in 2H 2017 as planned, with Betalutin® in patients with iNHL (FL and other subtypes) • First patient dosed with Betalutin® in Phase 1 dose-escalation study in DLBCLo The study is open for enrolment in the US and Europe • Decision made to initiate Phase 2 clinical studies to investigate the potential of Betalutin® combined with rituximab in 2nd line FLo Phase 2 trial expected to begin in 2H 2017 • Decision made to initiate Phase 1 clinical study to investigate the potential of Humalutin™ in NHLo Preclinical studies complete, Phase 1 trial expected to begin in 2H 2017 Post Period Events• Safety Review Committee approved continued evaluation of 20 MBq/kg Betalutin® with 100 mg/m2 lilotomab in a Phase 2 expansion cohort in Arm 4 • Updated results from LYMRIT 37-01 have been accepted for presentation at ICML in Juneo Safety and preliminary efficacy data from all evaluable NHL patients Financial Highlights First Quarter 2017(Figures in brackets = same period 2016 unless otherwise stated)• Revenues in the first quarter 2017 amounted to NOK 0.078 million (NOK 0.078 million)• Total operating expenses for the first quarter were NOK 65.8 million (NOK 52.7 million)• Comprehensive loss for the first quarter amounted to NOK 55.8 million (loss of NOK 64.1 million)• Cash and cash equivalents amounted to NOK 933.3 million at the end of March 2017(NOK 1 018.2 million at the end of December 2016). OutlookBuilding on the progress made in 2016, Nordic Nanovector’s operations remain on track. With a strengthened financial position, the company is now expanding and extending its strategy towards achieving its broader long-term ambitions beyond Betalutin® in NHL. These are centred on maximising the value of its novel targeted biopharmaceutical candidates across all stages of NHL and other major haematological cancer indications; to prepare for the commercialisation of Betalutin®; and to selectively extend its pipeline. The profile of Betalutin® is well differentiated within the competitive landscape. Encouraging preliminary results and good progress in the LYMRIT 37-01 clinical study give the company confidence that it is on track to initiate the pivotal Phase 2 PARADIGME trial during the second half of 2017. Management will continue to focus its efforts on the efficient execution of its plans and to meet clinical milestones. Current cash resources are expected to be sufficient to take the company beyond a first regulatory submission for Betalutin® in FL in the first half of 2019 and to meet value-generating clinical milestones in its other programmes.Presentation and webcast detailsA presentation by Nordic Nanovector’s senior management team will take place today at 8:30 a.m. CET at: Thon Hotel Vika AtriumMunkedamsveien 450250 Oslo Meeting Room: NYLAND The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2017 from 7:00 am CET today. For further information, please contact: IR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601 Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com Forward-looking statementsThis announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Nordic Nanovector ASA - resultater for første kvartal 2017

Oslo, 24 mai 2017 Nordic Nanovector (OSE: NANO) publiserer i dag resultater for første kvartal 2017. Selskapets ledelse vil gi en presentasjon av resultatene klokken 08:30 i Oslo - se ytterligere informasjon nedenfor. Nordic Nanovector rapporterer om fortsatt operasjonell fremgang i første kvartal. Den pågående kliniske fase 1/2-studien med Betalutin®i fremskreden, sakte-voksende lymfekreft av typen non-Hodgkins lymfom (iNHL) utviklet seg i tråd med planen. Studiens sikkerhetskomite godkjente fortsettelse av klinisk evaluering av 20 MBq/kg Betalutin®med 100 mg/m2lilotomab, hvilket gir anledning til å bygge en solid base med kliniske data. Ledelsen fastholder planen om oppstart av den endelige Fase 2 PARADIGME studien i andre halvår 2017. Den første pasienten ble behandlet i Fase 1 studien for fremskreden og tilbakevendende diffus storcellet B celle lymfom (DLBCL) med Betalutin®. Selskapet besluttet også å utvide undersøkelsene av sin anti-radionuklide-konjungat (ARC) for Fase 2 kombinasjonsstudien for Betalutin®og rituximab, og en fase 1 studie av Humalutin™, et kimert anti-CD37 ARC. Begge studiene er forventet å starte i løpet av andre halvår 2017. «Det sterke momentet fra 2016 fortsatte inn i første kvartal 2017. Jeg er fornøyd med den fremragende utviklingen Nordic Nanovector har i å utvide sine kliniske utviklingsprogrammer med Betalutin®i follikulært lymfom (FL) og nå også i DLBCL. Vi gleder oss også over planen knyttet til oppstart av nye kliniske studier senere i år. Disse kan utvide markedsmulighetene vesentlig for vår kreftsøkende ARC», sier administrerende direktør i Nordic Nanovector, Luigi Costa. Operasjonelle begivenheter i første kvartal 2017 · Fremdriften fortsetter mot oppstart av Fase 2 PARADIGME-studien i andre halvår 2017 som planlagt, med Betalutin®i pasienter med iNHL (FL og andre undergrupper) · Første pasient behandlet med Betalutin®i Fase 1 studien hvor dosen kan bli øket trinnvis for DLBCL · o   Studien er åpen for rekruttering i USA og Europe · Beslutning om oppstart av Fase 2 klinisk studie for å undersøke Betalutin®'s potensiale i kombinasjon med rituximab i andre linje FL · o   Fase 2-studie forventes å starte i andre halvår 2017 · Beslutning om å starte Fase 1 klinisk studie for å undersøke potensialet for Humalutin™for behandling av NHL · o   Prekliniske undersøkelser er gjennomført, Fase 1 studien forventes å starte i andre halvår 2017 Hendelser etter periodens slutt · Sikkerhetskomiteen godkjente fortsettelse av klinisk evaluering av 20 MBq/kg Betalutin®med 100 mg/m2lilotomab i en fase 2 utvidelse av Arm 4 · Oppdaterte resultater fra LYMRIT 37-01 har blitt godkjent for presentasjon på ICML-kongressen i juni · o   Sikkerhet og foreløpige tall for virkningsgrad fra alle evaluerbare NHL pasienter Finansielle høydepunkt første kvartal 2017 (Beløp i parentes = samme periode i 2016 dersom ikke annet er oppgitt) · Omsetningen i første kvartal 2017 ble 0,078 millioner kroner (0,078 millioner kroner) · Totale driftskostnader for første kvartal var 65,8 millioner kroner (52,7 millioner kroner) · Samlet tap for første kvartal beløp seg til 55,8 millioner kroner (tap på 64,1 millioner kroner) · Kontantbeholdningen beløp seg til 933,3 millioner kroner ved utgangen av mars 2017 (1 018,2 millioner kroner ved utgangen av desember 2016) Fremtidsutsikter Nordic Nanovectors utvikling følger plan og bygger videre på framgangen oppnådd gjennom 2016. Etter å ha ytterligere styrket kontantbeholdningen, er selskapet i gang med å utvide sine strategiske planer for å nå videre og mer langsiktige mål utover Betalutin®i NHL. Disse er sentrert om å maksimere verdien av selskapets målrettede biofarmasøytiske kandidater gjennom alle faser av NHL og andre store hematologiske kreftindikasjoner, å forberede kommersialiseringen av Betalutin®og selektivt utvide produktporteføljen. Betalutin®har en veldifferensiert produktprofil sammenlignet med sine konkurrenter. Det er så langt oppnådd lovende foreløpige resultater og det er god fremdrift i den kliniske studien Lymrit 37-01. Detter gir selskapet trygghet for å fastholde planen med oppstart av den endelige Fase 2 PARADIGME studien i annet halvår 2017. Ledelsen vil fortsette å rette innsatsen mot effektiv utøvelse av planer for å nå kliniske milepæler. Selskapets kontantbeholdning er forventet å være tilstrekkelig til å nå den regulatoriske godkjenningssøknaden for Betalutin®i første halvdel av 2019 og til å oppnå verdigenererende kliniske milepæler i de øvrige programmene. Informasjon om presentasjon og webcast Selskapets ledelse gir en presentasjon av resultatene i dag klokken 08:30. Sted: Thon Hotel Vika Atrium Munkedamsveien 45 0250 Oslo Møterom: NYLAND Presentasjonen kan følges direkte på www.nordicnanovector.com under Investor Relations / Webcast. Resultatrapporten og presentasjonen er tilgjengelig på www.nordicnanovector.com under seksjonen Investor Relations / Quarterly reports/ 2017 fra klokken 07:00 i dag. For ytterligere informasjon, vennligst kontakt Luigi Costa, adm. dir Tlf: +41 79 124 8601 Tone Kvåle, finansdirektør Tlf: 91 51 95 76 E-post: ir@nordicnanovector.com Om Nordic Nanovector Nordic Nanovector arbeider med utvikling og kommersialisering av innovativ behandling til pasienter for å møte store udekkede behandlingsbehov og videreutvikle kreftbehandling. Selskapet har ambisjoner om å bli en ledende aktør innen utviklingen av målrettet behandling for hematologisk kreft. Nordic Nanovectors ledende legemiddelkandidat under klinisk utvikling er Betalutin®, et målrettet CD37 antistoff-radionuklid-konjugat (ARC) utviklet for å forbedre og supplere dagens behandlingsalternativ for pasienter med lymfekreftformen non-Hodgkin's Lymfom (NHL). NHL er en indikasjon med et stort udekket behandlingsbehov og muligheter for såkalt «orphan drugs designation», en incentivordning for få frem nye legemidler til sjeldne sykdommer. NHL representerer er et voksende marked med et antatt markedspotensial på omkring 20 milliarder amerikanske dollar innen 2024. Selskapet har som mål å utvikle Betalutin®, både alene og i kombinasjon med andre behandlingsformer, for behandling av varianter av NHL, og regner med å sende den første regulatoriske søknaden for fremskreden follikulært lymfom i løpet av første halvår av 2019. Nordic Nanovector planlegger å beholde markedsføringsrettighetene og delta aktivt i kommersialiseringen av Betalutin®i viktige markeder. Selskapet arbeider også med utvikling av en produktportefølje med ARC og andre immunterapier for flere kreftindikasjoner. Ytterligere informasjon om selskapet er tilgjengelig på www.nordicnanovector.com Denne meldingen er informasjonspliktig etter verdipapirhandelloven §5-12.

Panoro Energy Announces First Quarter 2017 Results and Provides Operations and Corporate Updates

Oslo, May 24, 2017 - Panoro Energy (the “Company” or “Panoro” with OSE ticker: “PEN”) today announces the first quarter 2017 financial results and provides the following updates: Dussafu · Following completion of the divestment of a 25% working interest in Dussafu in April, BW Offshore has paid USD 11.0 million in cash plus some working capital adjustments and will provide a non-recourse loan of up to USD 12.5 million · First oil expected in 2H 2018 at an anticipated initial rate of 15,000 bopd Aje · Legal dispute still ongoing, with arbitration hearing anticipated during summer; certain JV partners held in contempt of UK Court Order · Third crude lifting and sale at Aje in Nigeria in March 2017, with proceeds attributed to settle cash calls post period-end · Aje-6 removed from the current drilling programme · Pacific Bora drillship has been demobilised from the Aje field after performing workover operations on the Aje-5 well. Result of Aje-5 side-track remains unknown at this time Corporate · Cash and cash equivalents of USD 11.9 million as at April 30, 2017, excluding USD 1.5 million held as security of costs in relation to the ongoing dispute on OML-113 Mr. John Hamilton, CEO of Panoro, commented: “We are very pleased to see Dussafu moving forward with speed, together with our new partner BW Energy. Although the legal dispute at Aje continues, we note that some of our OML 113 joint venture partners have recently been held in contempt of an order of the High Court of Justice of England and Wales. We will continue to take the necessary actions to protect our interests, and in the meantime will explore all options to unlock shareholder value.” Panoro will hold a conference call today at 08:30 a.m. CET, during which the Company will discuss the first quarter 2017 results. Participants are invited to ask questions about the fourth quarter report following the discussion. Participants are asked to dial-in five to ten minutes prior to the start time using the number and confirmation code below:  Local – Oslo, Norway                                   +47 21 563 318                                  Toll Free – Norway                                      800 19 457                                  Local – New York, USA                                +1 212 999 6659                                  Toll Free – USA                                             +1 866 966 5335                                  Local – London, UK                                       +44 (0) 203 003 2666                                  Toll Free – UK                                              0808 109 0700                                  Password:                                                    Panoro                                   Enquiries: Qazi Qadeer, Chief Financial OfficerTel:              +44 203 405 1060Email:          info@panoroenergy.com About Panoro Energy  Panoro Energy ASA is an independent E&P company based in London and listed on the Oslo Stock Exchange with ticker PEN. The Company holds production, exploration and development assets in West Africa, namely the Dussafu License offshore southern Gabon, and OML 113 offshore western Nigeria. In addition to discovered hydrocarbon resources and reserves, both assets also hold significant exploration potential. For more information, please visit the Company’s website at www.panoroenergy.com.

University Medical Centre Utrecht treats first cancer patient with Elekta Unity

UTRECHT, The Netherlands, May 24, 2017 – On May 19, the University Medical Centre (UMC) Utrecht treated the first patient as part of a clinical study with Elekta Unity, a magnetic resonance radiation therapy (MR/RT) system capable of delivering precisely targeted radiation doses and capturing magnetic resonance (MR) images of diagnostic quality. It is the first time a patient has been treated on a state-of-the-art linear accelerator with a high-field MR imaging system. The study, taking place at UMC Utrecht, aims to confirm the pre-clinically demonstrated technical accuracy and safety of Elekta Unity in the clinical setting. In the ongoing study, a total of five patients with spinal metastases will be treated with Elekta Unity under a strict protocol, and will receive radiation treatment guided by MR imaging. Analysis of the first clinically derived data shows that visibility of the treatment target and radiation beam accuracy is excellent as expected. “Image guided adaptive radiotherapy has become the standard of care to optimize the accuracy and precision of radiation delivery,” said Dr. Ina Jürgenliemk-Schulz, radiation oncologist at UMC Utrecht and principal investigator of the study. “Better visualization of the tumor targets and the surrounding healthy tissues at the exact moment of treatment, makes it possible to adapt the radiation dose to the actual tumor anatomy and optimally spare normal tissue during treatment. MR/RT with Elekta Unity will drive the paradigm shift from conventional highly fractionated treatments towards more ablative approaches, with smaller fields and fewer treatment fractions.” UMC Utrecht is the founding member of Elekta’s MR-linac Consortium, a global collaboration of institutions focused on uniting leaders in radiation oncology, MR-imaging, physics and radiotherapists. The mission of the Consortium is to investigate how MR-linac technology can lead to improved patient outcomes for existing radiation therapy indications and extend radiation therapy for additional indications. “Elekta Unity represents a significant scientific and engineering achievement, and the first treatment is a substantial milestone in the field of radiation therapy,” said Kevin Brown, Vice President Research and Innovation at Elekta. “This transformative MR/RT technology has the potential to change how cancer is treated and significantly improve patient outcomes. We are eager to advance this study in order to learn more about the real world clinical implications of the world’s only high-field MR-linac system.” Elekta Unity is the only MR/RT system that integrates a premium quality (1.5 Tesla) MR scanner, from MR technology partner Philips, with an advanced linear accelerator and intelligently designed software. To learn more, visit www.elekta.com/Unity. Elekta Unity is a work in progress and not available for sale or distribution. # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European Time Raven Canzeri, Global Public Relations ManagerTel: +1 770 670 2524, e-mail: raven.canzeri@elekta.comTime zone: EST: Eastern Standard Time About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Agromino: Invitation to Q1 Results Presentation

Agromino will publish its interim report for the first quarter of 2017 on Wednesday, 31 May 2017 at 08:00 CET. Analysts, investors and media are invited to attend a telephone conference that will be held at 09:00 CET on the same day.   Program: Simon Boughton, CEO and Konstantin Kotivnenko, Executive Board member, will present and comment upon the results. There will also be an opportunity to ask questions. To participate in the telephone conference, please call one of the following numbers: DK: +45 35 445 575FI: +358 981 710 494UK +442 030 089 808NO: +47 23 500 254SE: +46 856 642 690 The presentation material will be available on www.agromino.com   before the telephone conference starts. A recording of the telephone conference will be available afterwards on www.agromino.com . Investor enquiries  Mr. Simon Boughton, CEO of Agromino A/S Tel: +372 6191 500, e-mail:  mail@agromino.com  About Agromino  Agromino is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Agromino shares are traded on the main market of Nasdaq Stockholm. For subscription to Agromino A/S announcements please contact us: mail@agromino.com If you do not want to receive Agromino A/S press releases automatically in the future please send an e-mail to the following address: unsubscribe@agromino.com. This information is information that Agromino A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 23 May 2017.

Bittium exhibits its innovative products and solutions for neuroscience at the Second Moscow International Conference

Press release Free for publication on May 24, 2017 at 9am (CEST +1) Bittium exhibits its innovative products and solutions for neuroscience at the Second Moscow International Conference Oulu, Finland, May 24, 2017 – Bittium exhibits its innovative products and solutions for neurology at the Second Moscow International Conference "Non-invasive brain stimulation and functional brain mapping” on May 25th – 27th in Moscow, Russia. The main theme of the event is non-invasive brain stimulation methods in clinical practice and basic research. Bittium has over 10 years of experience with applications for neurophysiology during which the company has developed, for example, an electroencephalography (EEG) solution for TMS-EEG (EEG used during Transcranial Magnetic Stimulation) and fMRI-EEG (EEG used during Magnetic Resonance Imaging) applications. The products and solutions presented are NeurOne monitoring solution for neuroscience measurements and BrainStatus compact EEG amplifier. At the conference Bittium will have a speaking slot in Section C: “How can we improve results of NIBS (Non-invasive Brain Stimulation)?” on day one of the event. The presentation discusses about the Technical aspects of Real-time EEG triggered TMS stimulation. Bittium’s speaker is Simo-Pekka Simonaho, PhD., specialist neuroscience. Products presented at the conference: · NeurOne is one of the most accurate and quickest EEG measuring devices in the world designed for clinical and research use. NeurOne system enables fully synchronized group measuring of up to 30 persons simultaneously for example in different types of psychological studies. The solution is optimized for use with transcranial magnetic stimulators (TMS-EEG), with optional possibility to use it during magnetic resonance imaging procedures (fMRI-EEG). · BrainStatus is a wireless compact EEG amplifier, which is used together with a disposable easy and quick to wear BrainStatus electrode headband for example to diagnose epileptic seizures and brain stroke. BrainStatus enables quick measurement in field conditions as well as in hospitals, thus making the treatment process of the patient faster. More information on the offering: https://www.bittium.com/products__services/medical Further information: Arto PietiläSenior Vice President, Medical TechnologiesTel. +358 40 344 3507 Distribution:Main media Bittium Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. From November 2016 onwards, Bittium offers its customers also healthcare technology products and services in biosignal measuring in the areas of cardiology, neurology, rehabilitation, occupational health and sports medicine. Net sales in 2016 was EUR 64.2 million and operating profit was EUR 2.5 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com

President Online signs agreement for Cxense data management and personalization software

Oslo, Norway – 24 May 2017 – Cxense ASA (OSE: CXENSE) today announced that President Online, a leading Japanese magazine publisher, has signed an agreement with Cxense for use of data management and personalization software. President Online is a unit of President, Inc., which in 1963 published its first business magazine, President, as an overseas affiliate of Fortune. Today, the group issues a wide range of magazines and books covering business, work-life, politics, women and sports. These are also available through President Online as a subscription service. President Online will use the Cxense software to drive reader engagement and to optimize subscription offers.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide. Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: ir@cxense.comMobile: +47 906 60 062

Premiere for the new SAS food and drinks concept - “New Nordic by SAS”

Innovation has been a driving force for SAS in all 70 years the company has been airborne. SAS is now launching a new food and drinks concept on all its domestic, Scandinavian and European flights. The concept has been developed by SAS food and drinks managers in consultation with flyers and cabin crew as part of a major update of the SAS food and drinks range that focuses on natural ingredients and local suppliers.   “We know that food and drinks are an important part of the travel experience and are therefore delighted to be able to launch an entirely new concept where have dedicated tremendous attention to detail to ensure the packaging, quality of the food and experience itself are very much in line with the concept. We have reviewed everything from the packaging to how we serve the food to give our passengers an even better and more personal overall experience,” Stephanie Smitt Lindberg, VP Product and Development, SAS, says. The new design is unique to the industry and inspired by the takeaway culture. Lunch and dinner come prepacked in a cube that makes the contents very easy to eat while continuing to work, read or watch a movie.   The new menu includes Norwegian fjord salmon, Swedish lamb and Danish veal plus locally grown vegetables from Skags Gård farm. Accompaniments such as filled muffins will also be served along with main meals. The food and drinks are now available onboard Scandinavian and European flights and are included in the ticket price.  “We are on the constant look out for local producers that we can build a close relationship with and develop our menus together to ensure we serve ingredients that are in season, whether this be stone-baked bread from II Fornaio, asparagus grown at Stenhuse Gård Farm, handmade chocolates from Hedh Escalante or potatoes from Tollby Gård Farm,” Peter Lawrance, Head Chef and Menu Planner, SAS, says. The new food and drinks concept is part of the SAS New Experience  where SAS is also upgrading all its short and medium haul flights with new cabins and high speed WiFi.  The previous snacks and drinks range consisted of premium products from local Scandinavian suppliers. Favorite products from major international brands will continue to feature in the range, but the majority of products are from some of the largest brands in Scandinavia.    

Finland 100 years: Finnair showcases Finnish food culture with new collaborations

In conjunction with Finland’s upcoming centennial anniversary, Finnair is launching three new food collaborations for its onboard meals. The collaborations, which intend to promote Finland’s healthy and hearty food culture, are done in cooperation with the ELO Foundation, an association dedicated to the promotion of Finnish food culture. Business class for long-haul flights leaving Helsinki For business class customers flying out of Helsinki on long-haul flights between October 4 and January 9, Finnair’s Signature Menu chef, Eero Vottonen, has put together an exclusive 100 years-themed menu to celebrate the culinary nuances of Finnish food. The menu features delicacies such as Baltic herring, a Karelian stew and a cep mushroom soup flavored with cured elk. Vottonen, supported by the ELO foundation, finished sixth out of twenty-four participants at the prestigious Bocuse d’Or competition in Lyon, France last January. “When creating Finnair’s centennial menu, I reflected on what Finland and its food culture represent for me,” says Eero Vottonen. “It’s a big honor for me to collaborate with Finnair on this initiative and I’m excited to have the opportunity to introduce the tastes of Finland to thousands of passengers travelling through Finland with Finnair.” Business class for long-haul flights to Helsinki For business class customers flying to Helsinki on most long-haul flights between October 4 and January 9, Finnair will offer elements inspired by the Finland 100 years menu which was specially designed by the ELO Foundation to commemorate Finland’s centennial anniversary. The Finland 100 years menu served on Finnair’s flights will feature elements such as pickled salmon, rainbow trout and a Karelian stew with beef and pork. Variations of the ELO Foundation’s 100 years menu will also be served at Finnish embassies around the world to commemorate Finland’s centennial celebration. Economy class for long-haul flights For economy class customers on long-haul flights from July 5 to January 9, Finnair has partnered with the ELO Foundation and the Cygnaeus elementary school in Turku to create meals promoting Finland’s healthy and tasty school meals. Finland is world-renowned for its excellent school system, which also includes a free school meal for all children from grades one to nine, as well as for students in high schools and trade schools. The meals were selected by students from the Cygnaeus school in Turku during a workshop at Finnair’s catering premises, and tailored to fit the aircraft environment. The meals selected by the students include traditional Finnish favorites such as potatoes and meatballs as well as macaroni and meat casserole.   “Our main objective in partnering with the ELO Foundation on these great initiatives is to help promote Finland’s healthy and delicious food culture to hundreds of thousands of international passengers flying with us this year,” says Maarit Keränen, Head of in-flight service at Finnair. “For example, healthy and balanced school meals are an essential element of the well-recognized Finnish school system, and we are proud to highlight these tasty meals as part of our in-cabin service.” “We are extremely proud to take part in these collaboration initiatives with Finnair and to promote Finnish school meals in Finland and abroad,” says Seija Kurunmäki, Executive Director of the ELO Foundation. “Finland was the first country in the world to serve free school meals in 1943. Gradually, school meals in Finland have become more varied and are today part of a holistic pedagogic tool which extends far beyond the school lunch.” Finnair will also celebrate Finland’s 100 years by offering rye bread and Karelian pies during the meal service onboard its long-haul flights. Both items were in the top 3 when nearly 50 000 Finns voted in a public call to find Finland’s national food as a tribute to the country’s centennial anniversary. For additional information on the ELO Foundation, visit: http://www.elo-saatio.fi/en

ANNOUNCEMENT IN RELATION TO SETTLEMENT AGREEMENT WITH PERISAI PETROLEUM TEKNOLOGI BHD

The Board of Directors (the “Board”) of Emas Offshore Limited (the “Company”, together with its subsidiaries and associated companies) refers to its announcement made on 23 December 2016 (“23 December Announcement”) in relation to the Company’s entry into a settlement agreement (“Settlement Agreement”) with Perisai Petroleum Teknologi Bhd (“PPTB”) and the announcement made on 21 April 2017 in relation to the grant of an extension (“21 April Announcement”). All capitalised terms not defined shall have the same meaning as set out in the 23 December Announcement. Further to the 21 April Announcement, on 19 May 2017, PPTB issued a further written request to the Company for an extension of the Long Stop Period until 23 June 2017 (“2nd Extension”) on the basis that it would require more time to facilitate the Completion in accordance with the terms in the Settlement Agreement. The Company has since granted its consent to PPTB’s request for the 2nd Extension. Further announcements will be made by the Company and the Board via SGXNET and Newsweb as and when there are any material developments in compliance with the listing rules of the Singapore Exchange Securities Trading Limited and the Norwegian Securities Trading Act. When in doubt as to the action they should take, shareholders and potential investors should consult their financial, tax or other advisers. This announcement is subject to disclosure in accordance with section 5-12 of the Norwegian Securities Trading Act. By Order of the Board Shannon Ong Company Secretary 24 May 2017

Fazer Foodathon winner: Vegan Egg

An amazingly enthusiastic and diverse group of people from nuclear scientist to Michelin star chefs, from nutrition biotechnologists to marine biologists and from software developers to entrepreneurs and culinary management students spent their weekend at the Fazer Foodathon hacking together the food of the future. Divided into 10 teams, the Fazer Foodathon hackers were tackling two challenges - designing new plant-based dishes, cooking techniques and raw material combinations, and figuring out their ways on how to market them. The winning teams A prize of 5,000 euros was shared between three teams: Vegg, Oaty and Foodalytics. Egg International, the company behind the winning team Vegg, will be working with Fazer developing the concept further and introducing it to Fazer's customers. “We are excited to explore new products that will help us change the way we think about vegetarian food. We are looking for a product that is completely new, scalable, and has market potential”, said Jaana Korhola, Managing Director of Fazer Food Services Finland, and the chair of the Fazer Foodathon jury . The Fazer Foodathon presented a wide range of ideas - from new products and services to new concepts and food processing technologies. The winner, Vegg by Egg International, hacked traditional recipes, such as bread and pastry, with vegan egg made of tofu. One of the runner-ups, the Oaty team, aimed to diversify vegetarian food with products and snacks made of fermented oats. The other runner-up, Foodalytics (Super Food Girls) created a new concept of a magic spoon that collects data about your food intake and its environmental footprint and sends it to your phone so that you become more aware of how nutritious and environmentally-friendly a choice you have made. This team was also awarded by Arthur Potts-Dawson , the famous green chef from the UK who participated in the Fazer Foodathon as a mentor. Fazer welcomes collaboration, and encourages co-creation and innovation, and that is why the Fazer Foodathon was organinised. Fazer will discuss and co-create the ideas presented at the Fazer Foodathon further with the teams. With these ideas, Fazer aims to change people’s consumption patterns and turn plant-based food into a more mainstream option. Additional information: Sanna-Maria Hongisto, Senior Manager, Nutrition, Fazer Group, tel. +358 40 759 9936Fazer’s media phone line is open Mon–Fri from 8:00 to 16:00, tel. +358 40 668 2998Email addresses are in the form of firstname.lastname@fazer.com #fazerfoodathon #moregreens 

Nordic Nanovector ASA: Annual General Meeting held

Oslo, Norway, 24 May 2017 The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 24 May 2017 in Oslo, Norway. All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 2 May 2017 except item 13, authorisation to the Board to increase the share capital in connection with the option program. The Board will revert with an amended proposal for a long term share incentive program acceptable for all relevant parties. The complete minutes of the annual general meeting are attached to this release and also available on www.nordicnanovector.com. For further information, please contact: Ludvik Sandnes, Chairman Phone: +47 90 74 30 17 E-mail: lsandnes@nordicnanovector.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. 

Change in Pihlajalinna Plc’s Management Team

Pihlajalinna Plc           Stock Exchange Release     24 May 2017 at 14:00 Change in Pihlajalinna Plc’s Management Team Pihlajalinna Group’s CFO and member of the Management Team Niclas Köhler has resigned from his position in Pihlajalinna and will move on to Finavia. His employment ends on 30 June 2017. ”We have worked together with Niclas for many years. Our collaboration has been good and productive", says CEO Aarne Aktan. ”I’m sad about Niclas’s departure and wish him the best of luck with new challenges.” The search for a new CFO will be initiated immediately. Pihlajalinna Plc For further information, please contact:Aarne Aktan, CEO, +358 40 342 4440DistributionNasdaq HelsinkiKey mediainvestors.pihlajalinna.fi Pihlajalinna in briefPihlajalinna is one of the leading private social and healthcare services providers in Finland. The Company provides social and healthcare services for households, companies, insurance companies and public sector entities in private clinics, health centres, dental clinics and hospitals around Finland. Pihlajalinna provides general practitioner and specialised care services, including emergency and on-call services, a wide range of surgical services, occupational healthcare and dental care services, in private clinics and hospitals operating under the Dextra brand. Under the Pihlajalinna brand the Company, in cooperation with the public sector, offers social and healthcare service provision models to public sector entities with the aim of providing high quality services for public pay healthcare customers.

Seqr™ signs deal with iGaming Cloud

PRESS RELEASE  iGaming Cloud partners with Seqr™ enabling them to offer the innovative mobile payment solution as a new digital payment option for its customers. iGaming Cloud, part of the Gaming Innovation Group, is the first iGaming platform provider to sign with Seqr in order to offer the payment method to its customers. Customers will be able to top up and withdraw funds from their accounts by simply downloading the payment app and then using Seqr on their smartphone in both a secure and convenient way. A number of individual operators have already activated the Seqr services, or are in the process of doing so. The arrangement with iGaming Cloud is another example of Seqr’s penetration into the massively growing gaming market as it scales to many operators through one single integration. The deal will pave the way for Seqr to become available as a new payment method at approximately 40 operators using the iGaming Cloud’s platform. “Seqr fits well into our goals to eliminate technological bottlenecks and significantly reduce costs for operators and white labels solutions”, says Ian Bradbury, iGaming Cloud’s Head of Payment. “iGaming Cloud’s vision is to make the iGaming industry lean, and mobile devices are an important part of our everyday life, so it is a natural step for iGaming Cloud to engage the mobile channel in a broader way. Seqr makes the customer experience much simpler and more effective. Seqr also gives our customers (operators) the possibility to create attractive offers together with Seqr to help drive customer acquisition. On top of that there is the possibility to reach existing Seqr users directly through Seqr, which is very interesting”. “The partnership with iGaming Cloud and the Gaming Innovation Group is an important step in our strategy for greater market penetration into the iGaming industry,” says Peter Fredell, CEO at Seamless. “When Seqr was launched 4 years ago, the strategy was to approach the physical everyday merchants, such as supermarkets, convenient stores, fast food chains, parking etc., in order to create a Seqr user base before approaching niche industries such as iGaming. As we have now reached that goal with Seqr established in 16 countries, the timing is right to move into the iGaming industry”. The Gaming Innovation Group turned over 234 million euros during 2016. The gaming industry has been a contributor to Seqr’s existing business and this first partnership with a platform provider is an important step for further expansion into iGaming. About Seqr Seqr is the standard way to pay. Developed by Seamless, Seqr is the safe, fast and easy way to pay by mobile. The only thing the user needs is the Seqr app to scan a QR code or tap on the NFC terminal. Globally, over 30 million contactless card terminals now accept Seqr. The low investment and transaction fees for merchants and among others ensure that Seqr is the most widely used mobile payment solution in Europe. www.seqr.com About Seamless Seamless is one of the world’s largest suppliers of payment systems for mobile phones. Founded in 2001 and active in 35 countries, Seamless handles more than 5.3 billion transactions annually through 675 000 active sales outlets. Seamless has three main business areas including the transaction switch, the technology provider for the distribution of e-products and the mobile payment platform Seqr. www.seamless.se For more information, please contact: Dominique Tilleman - Head of Communications +32 473 27 04 90  Seamless Distribution AB, Box 6234, 102 34 Stockholm | Visiting address: St Eriksgatan 121 D | Org. no: 556610-2660 Phone: 08-564 878 00 | Fax: 08-564 878 23 | www.seamless.se

LINK Mobility Group ASA signs Term Sheet regarding acquisition of ViaNett AS

LINK Mobility Group ASA (LINK), one of Europe’s leading and fastest growing providers of B2C mobile messaging and mobile services, has entered into a term sheet regarding the acquisition of ViaNett AS and its fully owned subsidiary Sendega AS. LINK intends to acquire all shares in ViaNett AS from TargetEveryOne AB, a listed company on Nasdaq First North in Stockholm. ViaNett was established in 1998, and acquired Sendega AS in 2014. ViaNett has a total of 1.100 customers in Norway and Sweden. ViaNett/Sendega has experienced solid growth during the last years, and is expecting a 2017 revenue of NOK 94 million and an EBITDA of NOK 17 million. As part of the transaction, LINK will get the exclusive right to provide SMS gateway services to TargetEveryOne and its partners for a period of 4 years. ”We are very pleased to announce this agreement to acquire ViaNett and Sendega.  LINK will strengthen its position in the Norwegian and Swedish markets, broaden its range of mobile solutions services and increase its innovative capacity. After the acquisition, LINK will have a total of 7.400 enterprise customers that will all be offered attractive multimessaging and mobile solutions to assist them in the interaction with their customers“ says Arild E. Hustad, CEO of LINK. «We want to streamline our global strategy and focus even stronger on our core business by gaining market share in the world market with our scalable insight driven 1-to-1 marketing solution» says Bjørn Forslund, CEO of TargetEveryOne. The agreed enterprise value of the transaction is NOK 93.5 million, on a cash-free and debt-free basis and assuming a normalized level of working capital. The enterprise value is based upon an estimated EBITDA for ViaNett in 2017 of NOK 17 million multiplied by a factor of 5.5, and will be subject to adjustments if the actual EBITDA differs from the expected EBITDA. The purchase price under the transaction will, subject to customary adjustments, be settled as follows: · 1/3 of the purchasing price in cash upon closing · 1/3 of the purchasing price in shares in LINK valued at the share price at the Oslo Stock Exchange at the time of the announcement of the term sheet · 1/3 of the purchasing price as seller’s credit to be paid by equal monthly instalments over 24 months. Interest of 4.75% per annum is to be paid monthly The acquisition is conditional upon a satisfactory result of a confirmatory due diligence process to be performed by LINK, and upon LINK and the seller agreeing on the terms and conditions of a final share purchase agreement for the consummation of the transaction, containing, inter alia, customary closing conditions. LINK has a solid cash position due to strong cash flow from its operations and the successful placement of an EUR 50 million bond in February 2017. The cash part of the transaction will thus be fully financed through LINK's corporate fund and bond. The transaction is expected to close on or about 30 June 2017. For further information, please contact: IR Contact Siw ØdegaardLINK Mobility Group ASASiw.odegaard@linkmobility.comMob: +47 95 75 98 48 or CEO Bjørn ForslundTargetEveryOne ABbjorn@targeteveryone.comMob: +47 484 83 838 About LINK Mobility Group ASALINK is one of Europe’s leading and fastest growing providers of B2C mobile messaging and mobile services. LINK believe strongly in the power of mobilizing the interaction between businesses and consumers and have developed a range of attractive solutions to meet this growing demand and market trend. LINK is headquartered in Oslo, and has offices in Oslo, Bergen, Stockholm, Malmö, Copenhagen, Kolding, Tampere, Helsinki, Madrid, Hamburg, Riga and Tallinn. LINK has experienced stellar growth during the last years, in terms of both revenue and profits. In 2016 LINK delivered 3 billion mobile messages on behalf of its 6.300 customers, reporter a pro forma revenue of NOK 1 billion and had an adjusted EBITDA of NOK 122 million. About ViaNettViaNett is a specialist in mobile messaging and mobile payment, with a strong Norwegian and Swedish customer portfolio of 1.100 enterprise customers. ViaNett is No. 1 on donation solutions via SMS in Norway. ViaNett has experiences solid organic growth in revenue and profits during the last years. This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

TIGO: One of the top 25 multinational companies to work for in Latin America

TIGO made its way onto the list of the 25 best multinational companies to work for in the region after having been recognized on the local lists of El Salvador, Bolivia, Costa Rica, Guatemala and Paraguay, among the top places to develop a professional career. The TIGO operation in Honduras on its part was ranked among the best multinationals to work for in Central America last year, and the Colombian operation is working to measure the progress of its initiatives to elevate its already good leadership, employee engagement, and organizational culture in alignment with the GPTW Institute. Mauricio Ramos, CEO of Millicom, said: “We are convinced that a good work environment is the best way to obtain excellent business results and an essential element in having motivated employees. At the same time, the work that we do in the communities where we operate provides volunteering opportunities for our employees, making them part of a larger family and of a bigger mission that goes beyond their daily tasks. We are proud of this distinction because we work day after day to achieve that goal and to improve every year”. The award was received by Luis Arturo Torres, VP of Global Talent Management at Millicom, during the Great Place to Work for All annual conference. The company employs approximately 18,000 people worldwide. Each year, Great Place to Work, a consulting firm that specializes in workplace cultures, recognizes the best places to work in more than 45 countries worldwide. Its traditional ranking of the “Best Companies to Work For” is highly prestigious because it is based in large part on the opinions expressed by company employees in an anonymous and rigorous survey, in which the consulting firm gauges elements such as camaraderie, trust, and pride in belonging to the organization. Other aspects that are evaluated include the companies’ human resource practices and policies. Like in its 2016 edition, this year’s ranking of the 100 best companies to work for in Latin America was divided into three lists or categories: the 25 best multinationals, the 50 best small and medium-sized companies (between 50 and 500 employees), and the 25 best large workplaces (more than 500 employees). More information available at: www.greatplacetowork.net.

Telia Company and the other shareholders in Turkcell Holding have agreed on dividend distribution proposal to the General Assembly Meeting of Turkcell

Telia Company’s direct and indirect holding in Turkcell is 31.0 percent in total. Telia Company owns 7.0 percent directly and the remainder through its minority interest in Turkcell Holding. Provided that the General Assembly Meeting approves the proposal, Telia Company’s expected share of the above-mentioned dividends will be TRY 930 million. Based on a TRY/SEK 2.48 exchange rate, this corresponds to approximately SEK 2.3 billion pre tax and estimated to SEK 2.1 billion post tax.   For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany . Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.  We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com. 

LINK Mobility Group ASA signs Term Sheet regarding acquisition of ViaNett AS

LINK Mobility Group ASA (LINK), one of Europe’s leading and fastest growing providers of B2C mobile messaging and mobile services, has entered into a term sheet regarding the acquisition of ViaNett AS and its fully owned subsidiary Sendega AS. LINK intends to acquire all shares in ViaNett AS from TargetEveryOne AB, a listed company on Nasdaq First North in Stockholm. ViaNett was established in 1998, and acquired Sendega AS in 2014. ViaNett has a total of 1.100 customers in Norway and Sweden. ViaNett/Sendega has experienced solid growth during the last years, and is expecting a 2017 revenue of NOK 94 million and an EBITDA of NOK 17 million. As part of the transaction, LINK will get the exclusive right to provide SMS gateway services to TargetEveryOne and its partners for a period of 4 years. ”We are very pleased to announce this agreement to acquire ViaNett and Sendega. LINK will strengthen its position in the Norwegian and Swedish markets, broaden its range of mobile solutions services and increase its innovative capacity. After the acquisition, LINK will have a total of 7.400 enterprise customers that will all be offered attractive multimessaging and mobile solutions to assist them in the interaction with their customers“ says Arild E. Hustad, CEO of LINK. «We want to streamline our global strategy and focus even stronger on our core business by gaining market share in the world market with our scalable insight driven 1-to-1 marketing solution» says Bjørn Forslund, CEO of TargetEveryOne. The agreed enterprise value of the transaction is NOK 93.5 million, on a cash-free and debt-free basis and assuming a normalized level of working capital. The enterprise value is based upon an estimated EBITDA for ViaNett in 2017 of NOK 17 million multiplied by a factor of 5.5, and will be subject to adjustments if the actual EBITDA differs from the expected EBITDA. The purchase price under the transaction will, subject to customary adjustments, be settled as follows: · 1/3 of the purchasing price in cash upon closing · 1/3 of the purchasing price in shares in LINK valued at the share price at the Oslo Stock Exchange at the time of the announcement of the term sheet · 1/3 of the purchasing price as seller’s credit to be paid by equal monthly instalments over 24 months. Interest of 4.75% per annum is to be paid monthly The acquisition is conditional upon a satisfactory result of a confirmatory due diligence process to be performed by LINK, and upon LINK and the seller agreeing on the terms and conditions of a final share purchase agreement for the consummation of the transaction, containing, inter alia, customary closing conditions. LINK has a solid cash position due to strong cash flow from its operations and the successful placement of an EUR 50 million bond in February 2017. The cash part of the transaction will thus be fully financed through LINK's corporate fund and bond. The transaction is expected to close on or about 30 June 2017. For further information, please contact: IR Contact Siw ØdegaardLINK Mobility Group ASASiw.odegaard@linkmobility.comMob: +47 95 75 98 48 or CEO Bjørn ForslundTargetEveryOne ABbjorn@targeteveryone.comMob: +47 484 83 838 About LINK Mobility Group ASALINK is one of Europe’s leading and fastest growing providers of B2C mobile messaging and mobile services. LINK believe strongly in the power of mobilizing the interaction between businesses and consumers and have developed a range of attractive solutions to meet this growing demand and market trend. LINK is headquartered in Oslo, and has offices in Oslo, Bergen, Stockholm, Malmö, Copenhagen, Kolding, Tampere, Helsinki, Madrid, Hamburg, Riga and Tallinn. LINK has experienced stellar growth during the last years, in terms of both revenue and profits. In 2016 LINK delivered 3 billion mobile messages on behalf of its 6.300 customers, reporter a pro forma revenue of NOK 1 billion and had an adjusted EBITDA of NOK 122 million. About ViaNettViaNett is a specialist in mobile messaging and mobile payment, with a strong Norwegian and Swedish customer portfolio of 1.100 enterprise customers. ViaNett is No. 1 on donation solutions via SMS in Norway. ViaNett has experiences solid organic growth in revenue and profits during the last years.  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

LuxTurrim5G builds the key enablers for Digital SmartCity– Exel Composites supplies composite smart light poles to 5G network

Nokia Bell Labs driven industry group builds concrete enablers for future smart city with an ambitious three-year joint project called LuxTurrim5G. This will bring big data capacity available for companies and users through a network of smart light poles which include antennas and base stations for the novel fast 5G networks. The project includes technical development of the smart light poles with integrated 5G radio technology, different sensors and other devices as well as modern city planning and new digital services and business concepts related e.g. to security, navigation, smart lighting, weather monitoring, information sharing and advertisement. Concrete piloting will start already this year in Espoo, Finland. Our society and cities face great challenges to improve safety, energy efficiency, air quality, effectivity of transportation and quality of living. There is a growing need for a new generation digital service infrastructure for smart cities which enables improved data capacity for citizens and new service and business opportunities for companies. However, the capacity of mobile networks will be far too insufficient already in a few years due to the increased number of users and new digital services built and planned. This creates a serious bottleneck and threatens realization of the important smart city digital services which will be vital only if they are connected and distributed through an effective and reliable telecommunications network. This problem can be solved only by taking into use small cell radio frequency (RF) technologies and higher frequencies. This needs dense networks of antennas setting new requirements for the network infrastructure. LuxTurrim5G will solve these critical challenges by developing and demonstrating concrete technical solutions for smart light pole based 5G infrastructure, and business and service innovations based on that. The smart light poles being developed and piloted in the project including integrated miniaturized 5G antennas and base stations, different sensors, screens and other devices enable the realization of a novel smart city infrastructure bringing not only energy-efficient smart LED lighting but especially big data capacity and a variety of new smart city services available for all users. The project will also analyze what are the best practices to build the network, what cost items there are in planning, building and managing the network and how to share the cost of the network. Exel Composites develops the smart pole concept Exel Composites is a leading manufacturer of composite antenna radomes and structures to GSM, 3G and 4G base stations. Exel Composites also manufactures and develops e.g. airport approach lighting masts and other special masts to airports worldwide. “We have developed leading composite solutions to our customers’ GSM/3G and 4G solutions and we also want to be the partner for next generation solutions and utilize composites’ special features and optimization possibilities. We believe this concept brings along a totally new kind of solution to increase the data capacity in the future”, says Mikko Lassila, Product Business Owner, telecommunication, at Exel Composites. ”We need 5G networks for video surveillance as the current wireless networks do not provide enough capacity”, says Ilkka Ritakallio, Director, New Applications, R&D at Teleste”. “This ambitious multi-disciplinary joint R&D project gathers together ten innovative companies and three research institutes to develop and pilot the critical technical solutions regarding composite and antenna materials, smart light pole designs, miniaturized 5G base stations, integrated sensors as well as novel services and business models” says Coordinator of the project Markku Heino from Spinverse. The partners include Nokia Bell Labs, Exel Composites, Sitowise, Premix, Lammin Windows and Doors, Vaisala, Teleste, Indagon, C2 Smart Light, VTT, Tampere University of Technology (TUT), Aalto University and Spinverse. The project, set in first phase for three years, is funded by the companies and Tekes. LuxTurrim5G aims to proceed fast from R&D to piloting as the first parts of the novel 5G smart light pole based test network will be built in Nokia Campus Espoo already by the end of 2017. Espoo city is involved in the project supporting the implementation and learning the practical design aspects of smart city infrastructure. “The LuxTurrim pilot is a marvelous example of the ways Nokia and Espoo are building a smart city of the future and its requisite infrastructure in collaboration. Smart light pole networks will provide lucrative business opportunities for companies both large and small in the future”, says Tuula Antola, Director for Economic Development at City of Espoo. Nokia Bell Labs will develop high capacity low latency 5G mobile access and backhaul system to be deployed for small cells located in the street level e.g. in light poles and provide a full 5G test bed network (including connectivity to the TAKE-5 core test network of the 5G Test Network Finland) at Nokia HQ campus in Espoo for the use of all the consortium partners. Sitowise (earlier Sito) will act as a bridgebuilder between technological 5G solutions and the urban context and practical workflows through its expertise in planning and construction processes in urban environments. They will develop 3D design tools for smart city planning. ”Open, real-time data transfer is a key issue in a modern smart city merging the virtual and physical environments into one entity”, says project manager Anssi Savisalo from Sitowise. The research partners, TUT, VTT and Aalto university, bring versatile technical and scientific knowledge focusing the R&D both on materials and 5G RF technology and networks. The dedicated business development groups from the two latter ones lead the studies on novel business models and service concepts studying e.g. how and who can exploit the novel high data capacity networks business-wise, who are the potential key players, and what are the roles of cities, mobile operators and users. To make the transformation to the new generation smart city infrastructure possible, we need proof of concepts to test the technological opportunities and economic feasibility of this digital ecosystem. The digital ecosystem requires open interfaces and data access for different stakeholders and service providers. ”The goal of the project is to enable feasible digital service business opportunities for smart city environment, both on street level and in buildings. Big data capacity and a platform for novel services will improve the life and security of citizens enabling also autonomic traffic in near future”, emphasizes Director of the project Juha Salmelin from Nokia Bell Labs. LuxTurrim5G will be the breakthrough enabler for a digital smart city ecosystem in street level deployments, building versatile technology and service platform utilizing a single flexible 5G network. As an outcome, the project brings big data capacity available and provides an open access platform for new digital services – both technology and business-wise. The solutions related to smart 5G light poles, small cell 5G base stations, smart 5G light pole infra and related services will be demonstrated and business base for these products created - from pioneering proof-of-concept solutions to building new potential export business for Finnish companies. ”LuxTurrim5G is a good example of an ecosystem project with which one can take the 5G technologies being developed in Finland to new actors and environments as well as to form a basis for new business”, says Program Manager Mika Klemettinen from Tekes.

Turkcell General Assembly Meeting approved dividends proposal

In total, Turkcell will pay dividends of TRY 3,000 million of which Telia Company’s share will be TRY 930 million. Based on a TRY/SEK 2.48 exchange rate, Telia Company’s share corresponds to approximately SEK 2.3 billion pre tax and estimated to SEK 2.1 billion post tax.  "We are pleased that we were able to agree on a dividend between the shareholders in Turkcell Holding and that the AGM in Turkcell went as expected,” says Johan Dennelind, President and CEO Telia Company, and continues: "We are working hard to restore normal good corporate governance in Turkcell and with shareholder representation on the board, so that we can achieve an optimal capital structure in Turkcell."   For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .  Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.  We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at http://www.teliacompany.com/.

KONGSBERG - bringing 30mm firepower to the Czech Republic

KONGSBERG is offering the PROTECTOR MCT-30 turret for the upcoming Czech IFV program, where the systems will provide the Czech Armed Forces with highly accurate firepower for the tracked combat vehicles in the program. The turret is optimized for precision firing in static and moving scenarios, is highly reliable, and operated and reloaded from under armor. PROTECTOR MCT-30 supports various protection (armor) levels and is designed for customer specific tailoring and growth. In addition, the commonality of the MCT-30 user interface and use of similar components from the PROTECTOR systems already fielded in the Czech Army will reduce any training time and overall costs. "We are proud to have the Czech Republic as a customer, and we look forward to the opportunity to provide remotely turreted systems for this program", says Espen Henriksen, President of Kongsberg Protech Systems. "Since 2010 our company has delivered 100 PROTECTOR Remote Weapon Stations to the Czech Republic, providing their forces enhanced protection and state of the art technology. Not only has KONGSBERG delivered systems to the Czech Armed Forces, but we have established strong industrial relationships and continue to identify opportunities for local industry to work closely with KONGSBERG in building future capabilities." KONGSBERG has developed the innovative medium caliber turret by leveraging KONGSBERG`s extensive experience from remotely controlled weapon stations. The system design and selected sub-systems introduce new technologies that increase both performance and reliability for medium caliber weapon systems. The PROTECTOR MCT-30 turret, was selected for the US Army’s 2CR Stryker Brigade in December 2015, and is currently being produced and delivered for integration on the Stryker vehicle platforms. For further information, please contact:Pål Smørås, Director Marketing and Sales, Kongsberg Protech Systems. Mobile +47 954 81 233. KONGSBERG (OSE-ticker: KOG) is an international, knowledge-based group delivering high technology systems and solutions to clients within the oil and gas industry, merchant marine, defence and aerospace. KONGSBERG has 7 000 employees located in more than 25 countries and total revenues of NOK 15.8 billion in 2016. Follow us on Twitter: @kongsbergasa.

Trading in warrants series TO3 2017/2020 commences on May 29, 2017.

On Monday, May 29, 2017, Brighter AB's ("Brighter") warrants of series TO3 2017/2020, which was announced in conjunction with Brighter convertible notes series KV1 2017/2018 in April 2017, will be listed for trading. Terms of the warrants in brief: · Series TO3 warrants will be listed for trading on NASDAQOMX First North as of May 29, 2017. · Holding of one (1) warrants of series TO3 entitle the holder to subscribe for one (1) new share at a price of 5.12 SEK. · Subscription of shares on the basis of the warrants may take place during the following periods: · October 11, 2017 through October 25, 2017; · April 11, 2018 through April 25, 2018; · October 11, 2018 through October 25, 2018; · April 11, 2019 through April 25, 2019; · October 11, 2019 through October 25, 2019; · April 10, 2020 through April 24, 2020. · Holders of warrants series TO3 2017/2020 for a total value of SEK 500,000 or more may always exercise the warrants for subscription of shares. · Warrants of series TO3 have ISIN code SE0009947633. For terms and conditions of the Warrants, please visit: http://brighter.se/en/investors/documents/.   About Brighter AB (publ) Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on NASDAQOMX First North/BRIG . Visit our website and subscribe to press releases: www.brighter.se  Follow us on:    www.introduce.se Certified Adviser Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com. For further information, please contact: Henrik Norström, COO Telephone: +46 733 40 30 45 Email: henrik.norstrom@brighter.se Truls Sjöstedt, CEO Telephone : +46 709 73 46 00 Email: truls.sjostedt@brighter.se This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 14:30 CET on May 26 2016.